

CURRICULUM VITAE

NAME

Ralph Stuart Freedman, M.D., Ph.D.

PRESENT TITLE AND AFFILIATION:

Primary Appointment

Clinical Professor, Department of Gynecologic Oncology, The University of Texas
M. D. Anderson Cancer Center, Houston, Texas

(b) (6)

(b) (6)

OFFICE ADDRESS

Department of Gynecologic Oncology
U.T. M. D. Anderson Cancer Center, Unit 1362
P.O. Box 301439
Houston, Texas 77230
E-mail: rfreedma@mdanderson.org

EDUCATION

Degree-Granting Education

Witwatersrand University, Johannesburg South Africa, M.B. B. Ch., 1965

Witwatersrand University, Johannesburg South Africa, Ph.D., 1975

Postgraduate Training

Internship, General Surgery and Medicine, Johannesburg General Hospital,
Johannesburg, South Africa, 1966

Gynecology, Johannesburg General Hospital, South Africa, 1967

Obstetrics, Queen Victoria Maternity Hospital, Johannesburg, South Africa, 1967

Senior Internship, General Surgery and Urology, Baragwanath Hospital, South Africa,
January-June, 1968

Residency, Obstetrics and Gynecology, Johannesburg Group of Teaching Hospitals (Rotation
through Queen Victoria, Johannesburg and Baragwanath Hospitals), 1968-1971

Medical Officer (Emergency Room), Baragwanath Teaching Hospital, 1971

Faculty, University of Witwatersrand, Johannesburg Hospital Senior Medical Officer,
Department of Obstetrics & Gynecology, 1972-1973

Obstetrician & Gynecologist/Lecturer, University of Witwatersrand, Johannesburg, Department
of Obstetrics & Gynecology, 1973-1975

Fellowship, Department of Gynecology, U.T.M. D. Anderson Cancer Center, Houston,
Texas, 1976

External Beam, Interstitial and Intracavitary Dosimetry: Manual and Computer Methods
Calculation, The U.T.M.D. Anderson Cancer Center, Houston, Texas, 1977

CREDENTIALS

Board Certification

South Africa College of Physicians/Surgeons/Gynecologists, 1970

Royal College of Obstetricians and Gynecologists (London) (M.R.C.O.G), 1971

American Board of Obstetrics and Gynecology, Inc. , 1980

Other Certification

General Medical Council Certificate of full registration as a Medical Practitioner
in England, 1971

Licensure(s)

Active

State of Texas, (b) (6), 1977, 2/28/10

EXPERIENCE/SERVICE

Academic Appointments

Assistant Professor of Gynecology (tenure track), Division of Surgery, U.T. M.D. Anderson
Cancer Center, Houston, Texas, 1977-1981

Associate Professor of Gynecology (tenure track), Division of Surgery, U.T. M.D. Anderson
Cancer Center, Houston, Texas, 1981-1987

Professor of Gynecologic Oncology (tenured), Division of Surgery, U.T. M.D. Anderson Cancer
Center, Houston, Texas, 1987-2007

Clinical Professor of Gynecologic Oncology , Division of Surgery, U.T M D. Anderson Cancer
Centre, Houston, Texas, 2007- present

Member of the Graduate Faculty, Graduate School of Biomedical Sciences, UT Health Science
Center at Houston, Houston, TX, 10/1995-8/2007

Academic Administrative Appointments/Responsibilities

Chief and Director, Immunology and Molecular Biology Research, in department of Gynecologic Oncology, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1988-2007

Institutional Committee Activities

Co-Chair, Gynecologic Oncology Group Conference, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1986

Vice Chairman, Research Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1987-1988

Co-Chair, Surveillance Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1991-1992

Chair, Subcommittee, Economics in Clinical Research, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1992

Chair, Data Monitoring Committee for Clinical Trials, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1994-2000

Vice Chair, Surveillance Committee, (IRB), U.T. M.D. Anderson Cancer Center, Houston, Texas, 1994-2003

Vice Chair, Anderson Associates Steering Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1996-1997

Chair, Anderson Associates Steering Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1998-1999

Member, Medical Records Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1979-1984

Member, Research Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1980

Member, Surveillance Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1982

Member, Grand Rounds Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1984

Member, Annual Clinical Conference Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1984-1985

(b) (6)

Member, Investigational Drug Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1986-1987

Member, Laboratory Research Committee, Division of Surgery, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1986-1987

Member, Organizing Committee, Hybridoma, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1986

Ex Officio Member, Executive Committee of the Medical Staff, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1988-1989

Member, Faculty of Immunology, Graduate School of Biomedical Sciences, Houston, Texas, 1992-present

Member, Department of Clinical Immunology, Biologic Response Sciences, Ph.D. Program in Cancer Biology, Graduate School of Biomedical Sciences, Houston, Texas, 1992-1999

Member, Curriculum Committee for Clinical Oncology, Grand Rounds, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1992

Grievance Committee Member, Panel Chair, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1994-1995

Member, Gene Therapy Pharmacy Advisory Group, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1995

Member, Advisory Group to the Associate Vice President for Clinical & Translational Research, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1995-to date

Member, Executive Committee of the Prevention Faculty, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1995-1996

(b) (6)

Member, Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, 1995-2002

Member, Faculty Senate Ad Hoc Clinical Issues Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1996

Member, Faculty Classification Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1996-1999

Member, Anderson Associates Steering Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1996-2002

Member, Faculty of the Critical Issues in Human Research: Academic Creativity, Minority Participation, and Patient Care, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1996
Member, Faculty Senate - Committee for Institutional Restructuring, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1996

Member, Immunology Graduate Program, The University of Texas Graduate School of Biomed Sciences, Houston, Texas, 1997-2001

Member, Ambulatory Treatment Center Advisory Group, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1997-2001

Member, PRS Scientific Review Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1997-2001

Member, Steering Committee of the Human Cancer Gene Prevention and Therapy Program, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1998-1999

(b) (6)

Member, Ambulatory Treatment Center Chemotherapy & Infusion Units, Patients Services Advisory Group, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1998-2000

Member, Reproductive Biology Program, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1998-2001

Member, Study Section Review Committee for Clinical, Translational and Population-based Research Projects, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1999-2001

Member, PDMS/CORe System Advisory Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1999-2001

Member, Clinical Research Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 1999-2003

Chair, M.D. Anderson Associates Distinguished Alumnus Award Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 2000-2007

Member, Faculty Achievement Awards Parent Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 2001

Member, Program in Cell and Regulatory Biology, The University of Texas Graduate School of Biomed Sciences, Houston, Texas, 2001

Member, Historical Resources Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 2001-

Member, UCRC Director Search Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 2001-2002

Member, Keck Center (gene therapy) Steering Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 2001-2004

Member, Data Monitoring Committee, U.T. M.D. Anderson Cancer Center, Houston, Texas, 2003- 2009

Director, Media Preparation, Cancer Center Support Grant, 2003-2007

Chairman, Institutional Review Board 1, U.T. M.D. Anderson Cancer Center, 2004-2007

Ex Officio Member, Conflict of Interest Committee, U.T. M.D. Anderson Cancer Center, 2004-

Chairman, Executive Institutional Review Board, U.T. M.D. Anderson Cancer Center, 2007-

Other Appointments/Responsibilities

Consultantships

International Radiation Study Group, International Agency for Research, WHO Organization, and NCI, 1987

American Cancer Society, National Conference on Gynecologic Cancers, attended as Representative of Society of Surgical Oncology, 1992

Special Consultant, To National Federation of Cancer Centers of France, (Equivalent of the National Cancer Institute), 1993

Consultant to Medical Advisory Board, [REDACTED] (b) (4)

Consultant to [REDACTED] (b) (4) for Scientific Collaboration on ovarian cancer, 1998

Consultant to Albert Einstein Medical Center, Philadelphia, PA, Evaluation of scientific and clinical issues relating to GcMAF, 1999

Consultant for Korean telemedicine, consultation on tumor vaccines for KBS broadcasting team, 1999

Consultant, [REDACTED] (b) (4) 2000-2001

Chair, Subcommittee on the Development of New or Improved Instruments and Technologies for use in Research and Medicine Government Performance Review Act Working Group of the Advisory Committee to the NIH Director Bethesda, MD, 2000

Member, National Cancer Advisory Board, Washington, D. C., 2000-2006

Member, NCAB Subcommittees: (a) Budget; (b) Clinical Activities, and (c) Cancer Centers Chair, NCAB Subcommittee on Special Actions, 2002

Invited Guest, 23rd Annual Awards – General Motors Cancer Research Foundation, The Department of State, Washington, DC, June 6, 2001.

Food and Drug Administration, “Vaccines and Related Biological Products Advisory Committee Meeting, Bethesda, MD, November 28-29, 2001.

Ad Hoc Member, National Cancer Advisory Board Research Project Grant Working Group, NIH, Bethesda, MD, June 3, 2002

Chairman, NCAB Subcommittee on Special Actions, NIH, Bethesda, MD, 2002

Advisory Member, Data Safety Monitoring Board for protocol (b) (4), 2002-2005

Consultant, NIH/NCI Site Visit to EDRN Institution, Boston Clinical Epidemiology Center, November 20, 2002

Member, SCT Data Monitoring Policy Committee, Society of Clinical Trials, January 2004

Member, Ovarian Cancer Endpoints Workshop, FDA and ASCO, April 26, 2006

Member, FDA CDRH Immunology Device Panel, December 3, 2008

Member, FDA ODAC May, 2009 -

(b) (4) **Other Governmental Service**
N/A

HONORS AND AWARDS

Fellowship: Eli Lilly International Fellowship in immunology under the guidance of (b) (6) 1976

Special recognition award for outstanding contributions to teaching gynecologic oncology resident rotation at M.D. Anderson from St. Joseph's Hospital, 1982-1983

Fellow, American College of Obstetrics and Gynecology, Inc. (F.A.C.O.G), 1980

Fellow Royal College (by nomination) Obstetricians & Gynecologists, 1984

American Cancer Society 30th Annual Daytona Science Writer's Seminar, Daytona Beach, FL "Regional Active Immunization in Patients with Ovarian and Other Gyn Malignancies", 1988

Dean's Excellence Award Graduate School of Biomedical Sciences, 2000

America's Top Doctors, Castle Connolly Guide, 2001

(b) (6)

UT MD Anderson Cancer Center "Educator of the Month" January 2003

America's Top Doctors, Castle Connolly Guide, Third Edition, 2003

Dean's Excellence Award, Graduate School of Biomedical Sciences, 2003

America's Top Doctors, Castle Connolly Guide, Fourth Edition, 2004

America's Top Doctors, Castle Connolly Guide, Fifth Edition, 2005

America's Top Doctors, Castle Connolly Guide, Second Edition, 2006

RESEARCH

Grants and Contracts

Project Investigator, "Intraperitoneal priming with recombinant interferon- γ followed by recombinant interleukin-2 for *ex vivo* expansion of activated tumor infiltrating lymphocytes in IP adoptive immunotherapy of epithelial ovarian cancer" NIH, MO1-RR-02558, U.T. Health Science Center General Clinical Research Center Grant, 1995-2000, \$1,057,281

Co-Investigator/Project Director, "Correlated Clinical-Laboratory Phase I Trials", NCI, UO1 CA 62461, 1998-2003, \$1,671,168 (2/1/99-1/31/00) \$90,112

Co-Principal Investigator, "Laboratory Studies with Intraperitoneal rhIL12 Therapy", NCI, 1R55 CA 77241, Shannon Award to R. Lenzi, M.D., 1998-2000, \$100,000

Principal Investigator, "B7.1 Costimulation in Ovarian Cancer", NCI, R21 CA-80822 2000-2001, \$292,516 (Direct costs \$98,269)

Principal Investigator, "Phase II intraperitoneal rhIL-12", NCI R21 CA-91555, 2001-2005, \$307,500 (Direct costs \$225,000)

Mentor, "Correlated Clinical-Laboratory Phase I Trials" Minority Supplement, NCI, UO1 CA-62461-07, James L. Abbruzzese, M.D., PI, (b) (6) M.S., graduate student, 2001-2003, \$40,097 (Direct costs \$5,173)

Collaborator, "Early Therapeutic Development with Phase II Emphasis," NCI, NO1 CM-17003-04 (PP-24), Razelle Kurzrock, M.D., PI, 3/1/01-12/31/05 (Direct costs \$12,536)

Principal Investigator,

(b) (4)

(pending)

Funded Protocols/Contract Support

PI, [REDACTED] (b) (4)

PI, [REDACTED] (b) (4)

PI, [REDACTED] (b) (4)

PI, [REDACTED] (b) (4)

PI, [REDACTED] (b) (4)

PI, [REDACTED] (b) (4)

PI, [REDACTED] (b) (4)

PI, [REDACTED] (b) (4)

PI, [REDACTED] (b) (4)

PI, [REDACTED] (b) (4)

PI, [REDACTED] (b) (4)

[REDACTED] (b) (4)

Patents Granted and Pending

U.T. M.D. Anderson Cancer Center, Tumor Cell Surface Binding Monoclonal Antibodies, U.S.,
UTSC:216 Ralph S. Freedman, M.D., Ph.D., Principal Investigator; July 18, 1995

Grant Reviewer/Service on NIH/Other Study Sections

Special Review Committee, National Cancer Institute Lead Reviewer, RFA CA-92-28 Clinical
Trials of Cancer Therapy with Biological Response Modifiers, 1993

Special Review Committee, National Cancer Institute Lead Reviewer, National Cancer Institute
RFA CA 94-04 New Therapeutic Approaches for Breast Cancer, 1994

Special Review Committee, National Aeronautics and Space Administration, Biotechnology Cell Science Panel, 1996

Special Reviewer, Memorial Sloan Kettering Cancer Center, 2 PO1 CA52477-08, Epithelial Ovarian Cancer Program Project, 1997

Special Reviewer, United States-Israel Binational Science Foundation, Evaluation of Research Grants, 1998

Special Review Committee, National Cancer Institute Reviewer Clinical Research Studies Committee, 1998

Special Review Committee National Cancer Institute, Reviewer (site visit University of California, Los Angeles) Genetic Immunotherapy of Cancer, 1998

Special Review Committee, 1 PO1 CA-84266-01 - Dr. (b) (6), Mt. Sinai School of Medicine, New York, NY, 2000

NCI Sponsored Workshop, Colorectal Cancer Screening Workshop, Bethesda, MD, 2001

NCI Gynecologic Cancers Progress Review Group, Immunology Roundtable Session, Herndon, VA, June 18-20, 2001

Scientific Advisory and Consultant Staff, Food and Drug Administration, Rockville, MD, 2001

Peer Review Referee, Clinician Scientist Fellowship 2007/2008-Dr. (b) (6), Medical Research Council, London, January 2007

Peer Review Referee, Clinician Scientist Fellowship 2007-2011-Dr. (b) (6), Medical Research Council, London, February 2007

Referee United States-Israel Binational Science Foundation 2010.

PUBLICATIONS

a. Articles in Peer Reviewed Journals:

1. **Freedman RS**, Berry A. Progesterone deficiency in pregnancy. *S.A. J Obstet Gynaec* 8:72-76, 1970.
2. Gordon Y, **Freedman RS**. Premature rupture of membranes. *S.A. J Obstet Gynaec*, 1971.
3. **Freedman RS**. Aspects of Bantu Domestic life in relation to some gynaecological conditions. *S.A. Med J* 46:383, 1972.

4. **Freedman RS.** Gynaecology in Southern Africa (Charleswood, G.P., Witwatersrand University) 43:344-364, 1972.
5. **Freedman RS,** Joosting ACC, Ryan JT, Nkoni S. A study of associated factors, including genital herpes, in black women with cervical carcinoma in Johannesburg. *S.A. Med J* 48:1747-1752, 1974.
6. **Freedman RS,** Van der Walt A. Human placental lactogen (HPL) and plasma free Oestriol (OE3) values in the third trimester of pregnancy. *S.A. J Clin Lab Med* 77:1777-1780, 1975.
7. **Freedman RS.** Editorial - The importance of breast feeding. *S.A. J Obstet Gynaec* March 19, 1975.
8. **Freedman RS.** Histology and histochemistry of the ovary during pregnancy and in the postpartum period. *S.A. J Obstet Gynaec* 49:1226-1227, 1975.
9. **Freedman RS.** Pathophysiology of anovulation. In: *The Leech*. Witwatersrand University Press, 1976.
10. **Freedman RS.** The postpartum Endometrium. *S.A. J Med Sci* 41(2):99, 1976.
11. **Freedman RS,** Van der Walt A. Treatment of anovulation with human menopausal gonadotropin. *S.A. Med J* 50(13):519, 1976.
12. Schoub BD, Jacobs UR, Hyten E, **Freedman RS.** The role of mycoplasma in human infertility. *S.A. Med J* 50(11):571, 1976.
13. **Freedman RS,** Van der Walt A. The significance of serum oestradiol and progesterone levels in evaluating the response to clomiphene citrate. *S.A. Med J* 50(30):1171-1172, 1976.
14. Foden AP, **Freedman RS,** Abrahams C. S.E.M. of normal uterine cervix carcinoma in situ and squamous cell carcinoma: Preliminary findings. *S.A. Med J* 50(15):571, 1976.
15. **Freedman RS,** Wharton JT, Rutledge FN, Sinkovics JG. Transfer factor and possible applications in gynecology. *Am J Obstet Gynecol* 130(5):572-584, 1978.
16. **Freedman RS,** Bowen JM, Leibovitz A, Pathak S, Silciliano MJ, Gallagher HS, Giovanella BC. Characterization of an ovarian carcinoma cell line. *Cancer* 42(5):2352-2359, 1978.
17. Wallace S, Jing BS, Zornoza J, Hammond JA, Hamberger A, Herson J, **Freedman RS,** Wharton JT. Current concepts in cancer: Updated cervix cancer II. Stages IB and II. Is lymphangiography worthwhile? *Int J Radiat Oncol Biol Phys* 5:1863-1876, 1979.
18. **Freedman RS,** Bowen JM, Herson J, Wharton JT, Rutledge FN. Tumor Antigenicity and the immune system in gynecological cancer: A review. *Gynecol Oncol* 9:43-62, 1980.

19. **Freedman RS**, Herson J, Bowen JM, Wharton JM, Rutledge FN, Hamberger AD. Virus modified homologous tumor cell extract in the treatment of vulvar carcinoma. *Cancer Immunol Immunother* 8:33-38, 1980.
20. **Freedman RS**, Herson J, Wharton JT, Rutledge FN. Single-agent chemotherapy for recurrent carcinoma of the cervix. *Cancer Clin Trials* 3:345-350, 1980.
21. Hammond JA, Herson J, **Freedman RS**, Hamberger AD, Wharton JT, Wallace S, Rutledge FN. The impact of lymph node status on survival in cervical carcinoma. *Int J Radiat Oncol Biol Phys* 7:1713-1718, 1981.
22. Carlson JA, **Freedman RS**, Wallace S, Chuang VP, Wharton JT, Rutledge FN. Intra-arterial cisplatin in the management of squamous cell carcinoma of the uterine cervix. *Gynecol Oncol* 12:92-98, 1981.
23. **Freedman RS**. Methotrexate in gestational trophoblastic disease. *The Cancer Bulletin (MDACC)* 33(2):63-66, 1981.
24. Boice CR, **Freedman RS**, Herson J, Wharton JT, Rutledge FN. Bleomycin and Mitomycin-C (BLLM) in recurrent squamous uterine cervical carcinoma. *Cancer* 49(11):2242-2245, 1982.
25. **Freedman RS**, Bowen JM, Leibovitz A, Pathak S, Siciliano MJ, Gallager HS, Giovanella BC. Characterization of a cell line (SW756) derived from a human squamous carcinoma of the uterine cervix. *In Vitro* 18(8):719-726, 1982.
26. Fritsche HA, **Freedman RS**, Liu F, Acomb LD, MT. (ASCP), and Collingsworth W. A survey of tumor markers in patients with squamous cell carcinoma of the uterine cervix. *Gynecol Oncol* 14:230-235, 1982.
27. Hannigan EV, **Freedman RS**, Elder KW, Rutledge FN. Treatment of advanced sarcoma with Adriamycin. *Gynecol Oncol* 16(1):101-104, 1983.
28. Hannigan EV, **Freedman RS**, Elder KW, Rutledge FN. Re-exploration after treatment for uterine sarcoma. *Gynecol Oncol* 16(1):1-5, 1983.
29. Hannigan EV, **Freedman RS**, Rutledge FN. Adjuvant chemotherapy in early uterine sarcoma. *Gynecol Oncol* 15(1):56-64, 1983.
30. Hannigan EV, **Freedman RS**, Elder KW, Rutledge FN. Treatment of advanced uterine sarcoma with Vincristine, Actinomycin-D and cyclophosphamide. *Gynecol Oncol* 15:224-229, 1983.
31. Jolles CJ, **Freedman RS**, Jones LA. Estrogen and progesterone therapy in advanced ovarian cancer: Preliminary report. *Gynecol Oncol* 16:352-359, 1983.
32. **Freedman RS**, Gutterman JU, Wharton JT, Rutledge FN. Leukocyte interferon (IFN- α) in patients with epithelial ovarian carcinoma. *J Biol Res Mod* 2(2):133-138, 1983.

33. **Freedman RS**, Bowen JM, Herson JH, Wharton JT, Edwards CL, Rutledge FN. Immunotherapy for vulvar carcinoma with virus-modified homologous extracts. *Obstet Gynecol* 62(6):707-714, 1983.
34. Jones LA, Edwards CL, **Freedman RS**, Tan MT, Gallager HS. Estrogen and progesterone receptor titers in primary epithelial ovarian carcinomas. *Int J Cancer* 32(2):567-571, 1983.
35. Horbelt DV, **Freedman RS**, Roberts DK, Walker NJ, Edwards CL, Jones LA. An ultrastructural comparison of grade I and II endometrial adenocarcinoma considering estrogen and progesterone receptor status. *Gynecol Oncol* 18:150-156, 1984.
36. **Freedman RS**, Bowen JM, Atkinson EN, Scott W, Wagner S. Virus-augmented delayed hypersensitivity skin tests in gynecological malignancies. *Cancer Immuno Immunother* 17:142-146, 1984.
37. Lotzová E, Savary CA, **Freedman RS**, Bowen JM. Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract. *Cancer Immuno Immunother* 17:124-129, 1984.
38. Davis JW, **Freedman RS**, Atkinson N, Bowen JM. Augmentation of *in vitro* lymphocyte blastogenesis and cytotoxicity responses by tumor cells modified with dodecanoyl Cytochrome C. *Nat Immu Cell Growth Reg* 3:203-209, 1983/4.
39. Keeney ED, **Freedman RS**, Drewinko B, Rutledge FN, Atkinson EN. Clinical evaluation of high-dose cytarabine and cisplatin in recurrent cervical carcinoma. *Cancer Treat Rep* 69(9):1023-1025, 1985.
40. Shirey DR, Kavanagh JJ, Gershenson DM, **Freedman RS**, Copeland LJ, Jones LA. Tamoxifen therapy of epithelial ovarian cancer. *Obstet Gynecol* 66:575-578, 1985.
41. Gershenson DM, Copeland LJ, Kavanagh JJ, Cangir A, Del Junco G, Saul PB, Stringer CA, **Freedman RS**, Edwards CL, Wharton JT. Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with Vincristine, Dactinomycin, and Cyclophosphamide. *Cancer* 56:2756-2761, 1985.
42. Jolles CJ, **Freedman RS**, Hamberger AD, Horbelt DV. Complications of extended-field therapy for cervical carcinoma without prior surgery. *Int J Rad Oncol Biol Phys* 12:179-183, 1986.
43. **Freedman RS**, Saul PB, Edwards CL, Jolles CJ, Gershenson DM, Jones LA, Atkinson EN, Dana WJ. Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: A Phase II Study. *Cancer Treat Rep* 70:369-373, 1986.
44. Savage HE, Rossen RD, Hersh EM, **Freedman RS**, Bowen JM, Plager G. Antibody development to viral and allogeneic tumor cell associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus infected tumor cells. *Cancer Res* 46:2127-2133, 1986.

45. Cox CJ, **Freedman RS**, Fritsche HA. Lacto-N-Fucopentaose III activity in the serum of patients with ovarian carcinoma. *Gynecol Obstet Invest* 21:164-168, 1986.
46. Hancock KC, **Freedman RS**, Edwards CL, Rutledge FN. Use of cisplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium. *Cancer Treat Rep* 70(6):789-791, 1986.
47. Roberts DK, Lavia LA, **Freedman RS**, Horbelt DV, Busby-Walker N. Nuclear and nucleolar areas: A quantitative assessment of endometrial neoplasia. *Obstet Gynecol* 68:706-708, 1986.
48. Malone JM, Koonce T, Larson DM, **Freedman RS**, Carrasco CH, Saul PB. Palliation of small bowel obstruction by percutaneous gastrostomy in patients with progressive ovarian carcinoma. *Obstet Gynecol* 68:431, 1986.
49. Lotzová E, Savary CA, **Freedman RS**, Bowen JM. Natural immunity against ovarian tumors. *Comparative Immunology, Microbiology, and Infectious Diseases* 9:269-275, 1986.
50. Ordonez NG, **Freedman RS**, Herlyn M. Lewis and related tumor-associated determinants on ovarian carcinoma. *Gynecol Oncol* 26:1-10, 1987.
51. Adelson MD, Johnson TS, Sneige N, Williamson KD, **Freedman RS**, Peters LJ. Cervical carcinoma DNA content, S-fraction, and malignancy grading: Part II. Comparison with clinical staging. *Gynecol Oncol* 26:57-70, 1987.
52. Larson DM, Copeland LJ, Gallagher HS, Gershenson DM, **Freedman RS**, Wharton JT, Kline RC. Nature of cervical involvement in endometrial carcinoma. *Cancer* 59:959-962, 1987.
53. Gershenson DM, Kavanagh JJ, Copeland LJ, Edwards CL, **Freedman RS**, Wharton JT. High-dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus. *Cancer* 59:1264-1267, 1987.
54. Kline RC, **Freedman RS**, Jones LA, Atkinson EN. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen citrate and medroxyprogesterone acetate. *Cancer Treat Rep* 71(3):327-328, 1987.
55. Metz CA, **Freedman RS**, Magrina JF. Methylprednisolone in cisplatin induced nausea and emesis: A placebo controlled trial. *Gynecol Oncol* 27:84-89, 1987.
56. **Freedman RS**, Edwards CL, Bowen JM, Lotzova E, Katz R, Lewis E, Atkinson EN, Carsetti R. Viral oncolysates in patients with advanced ovarian cancer. *Gynecol Oncol* 29:337-347, 1988.
57. Kong JS, Peters LJ, Wharton JT, Ang KK, Delclos L, Gershenson DM, Copeland LJ, Edwards CL, **Freedman RS**, Saul PB, Stringer CA. Hyperfractionated split-course whole abdominal radiotherapy for ovarian carcinoma: Tolerance and toxicity. *Int J Radiation Oncol Biol Phys* 14:737-743, 1988.

58. Lotzova E, Savary CA, **Freedman RS**, Edwards CL, and Wharton JT. Recombinant IL-2 activated NK cells mediate LAK activity against ovarian cancer. *Int J Cancer* 42:225-231, 1988.
59. **Freedman RS**. Gestational trophoblastic disease. *Oncology Overview*. September, 1988.
60. **Freedman RS**, Bowen J, Delclos L, Atkinson E, Lotzová E, Wharton JT, Edwards CL, Scott W, Patenia B, Bass S. Randomized comparison of viral oncolysate plus radiation and radiation alone in uterine cervix carcinoma. *Am J Clin Oncol (CCT)* 12(3):244-250, 1989.
61. Ioannides CG, Platsoucas CD, Bowen JM, Wharton JT, and **Freedman RS**. Increased ovarian tumor cell surface reacting antibodies in patients with ovarian adenocarcinoma after viral oncolysate therapy. *Anticancer Res*. 9:81-86, 1989.
62. Gershenson DM, Wharton JT, Copeland LJ, Stringer CA, Edwards CL, Kavanagh JJ, and **Freedman RS**. Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide. *Gynecol Oncol* 32:336-341, 1989.
63. Ioannides CG, Platsoucas CD, O'Brian CA, Patenia R, Bowen JM, Wharton JT, and **Freedman RS**. Viral oncolysate in cancer treatment: Immunological mechanism of action. *Anticancer Res* 9:535-544, 1989.
64. Ioannides CG, **Freedman RS**, and Platsoucas CD. OKT4 monoclonal antibody-induced activation of an autoreactive T cell clone. *Cellular Immunol* 123:244-252, 1989.
65. **Freedman RS**, Kouttab NM, Bowen JM, Edwards CL and Katz RL. Lymphokine activity in malignant effusion after intracavitary viral oncolysates. *Lymphokine Res* 8:2:115-122, 1989.
66. O'Keefe F, Carrasco CH, Charnsangavej C, Richil WR, Wallace S, and **Freedman RS**. Percutaneous drainage and feeding gastrostomies in 100 patients. *Radiology* 172:341-343, 1989.
67. Tatman JL, **Freedman RS**, Scott W, and Atkinson EN. Treatment of advanced endometrial adenocarcinoma with cyclic sequential ethinyl estradiol and medroxyprogesterone acetate. *Eur J Cancer Clin Oncol* 25:1619-1621, 1989.
68. Furukawa K, Lotzová E. **Freedman RS**, Bowen JM, Edwards CL, and Wharton JT. Effect of virus-modified tumor cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian carcinoma. *Cancer Immunol Immunother* 30:126-132, 1989.
69. Sandles LG, **Freedman RS**, Raber MN, Kavanagh J, Edwards CL, Scott W. and Wharton JT. Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies. *Gynecol Oncol*. 39: 139-145, 1990.
70. **Freedman RS**, and Ioannides CG. Biological response modifiers in the treatment of gynecologic malignancies. *The Cancer Bulletin*. 42:98-105, 1990.

71. Lotzová E, Savary CA, **Freedman RS**, Edwards CL, and Morris M. Comparison of rIL-2 activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: Cytotoxicity grown kinetics and phenotype. *Cancer Immunol Immunother* 31:169-175, 1990.
72. Ioannides CG, Platsoucas CD, and **Freedman RS**. Immunological effects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates. *In Vivo* 4:17-24, 1990.
73. Ioannides, CG, **Freedman, RS**, Liskamp, R., Ward, NE, and O'Brian, CA. Inhibition of IL-2 receptor induction and IL-2 production by a novel PKC peptide inhibitor N-m-KRTLRL. *Cellular Immunol* 131:242-252, 1990.
74. Riley LB, Pellis NR, Schantz SP, **Freedman RS**, Balch CM, and Itoh K. Humoral modulations of lymphokine-activated killer (LAK)-cell induction in humans: IgG-related and non-IgG inhibitors in sera from cancer patients. *Int J Cancer* 46:785-791, 1990.
75. Ioannides CG, Platsoucas CD, Patenia R, Kim Y-P, Bowen, JM, Edwards CL, Morris M, Wharton JT, and **Freedman RS**. T-cell functions in ovarian cancer patients treated with viral oncolysates: Increased helper activity to immunoglobulins production. *Anticancer Res* 10:645-653, 1990.
76. Ioannides CG, **Freedman RS**, Patenia R, Bowen JM, Ward NE, O'Brian CA. Immunological effects of tumor vaccines: III. Influenza virus oncolysates inhibit the TPA induced activation of peripheral blood mononuclear cells. *In Vivo* 5:1-6, 1991.
77. **Freedman RS**, Ioannides CG, Tomasovic B, Patenia R, Zhang H-Z, Liang J, and Edwards CL. Development of a cell surface reacting human monoclonal antibody agent in ovarian carcinoma. *Hybridoma* 10:21-33, 1991.
78. Ioannides CG, **Freedman RS**, Rashed S, Platsoucas CD, and Kim Y-P. Cytotoxic T cell clones isolated from ovarian tumor infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. *J Immunol*, 146:1700-1707, 1991.
79. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL and **Freedman RS**. Tumor cytotoxicity by lymphocytes infiltrating ovarian malignant ascites. *Cancer Res* 51:4257-4265, 1991.
80. Ioannides CG, Rashed S, Fisk B, Fan D, Itoh K, **Freedman RS**. Lymphocytes infiltrating ovarian malignant ascites: Modulation of IL-2 induced proliferation by IL-4 and of selective increase in CD8⁺ T cells by TNF- α . *Lymphokine, Cytokine Res* 10:307-315, 1991.
81. Ioannides CG, and **Freedman RS**. Selective usage of TCR V α in tumor specific CTL lines isolated from ovarian tumor associated lymphocytes. *Anticancer Res*. 11:1919-1926, 1991.
82. **Freedman, RS**. Biologic response modifiers in gynecologic malignancies. *Cancer Bulletin* 43:139-145, 1991.

83. Burke TW, Stringer CA, Morris, M, **Freedman RS**, Gershenson DM, Kavanagh JJ and Edwards, CL. Prospective treatment of advanced recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. *Gynec Oncol* 40:264-267, 1991.
84. Fromm G-L, **Freedman RS**, Fritsche HA, Atkinson EN, and Scott W. Sequentially administered ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors. *Cancer* 68:1885-1889, 1991.
85. Ioannides CG, and **Freedman RS**. T cell responses to ovarian tumor vaccines. *Internat Rev Immunol* 7:349-364, 1991.
86. Ioannides CG, Fisk B, Tomasovic B, Pandita R, Aggarwal BB and **Freedman RS**. Induction of IL-2 receptor by tumor necrosis factor alpha on cultured ovarian tumor associated lymphocytes. *Cancer Immunol Immunother* 35:83-91, 1992.
87. **Freedman RS**, Ioannides CG, Mathioudakis G, and Platsoucas CD. Novel immunologic strategies for the treatment of ovarian carcinoma based on cell surface recognition. *Am J Obstet Gynecol* 167:1470-1478, 1992.
88. Kooi S, **Freedman RS**, Rodriguez-Villanueva J, and Platsoucas CD. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma. Tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. *Lymphokine and Cytokine Res* 12:429-437, 1993.
89. Kirk IR, Carrasco CH, Lawrence DD, Chuang VP, Richli WR, Charnsangavej C, Kavanagh JJ, Kudelka AP, **Freedman RS**, Markowitz B. Percutaneous placement of intraperitoneal catheters under fluoroscopy. *J Vascular Intervent Radiol* 4:299-304, 1993.
90. Kudelka AP, **Freedman RS**, Edwards CL, Lippman SM, Tornos CS, Krakoff IH, Kavanagh JJ. Metastatic adenocarcinoma of the endometrium treated with 13-CIS-Retinoic acid plus interferon- α . *Anti-Cancer Drugs* 4(3):335-337, 1993.
91. Ioannides CG, Fisk B, Pollack MS, Frazier ML, Wharton JT and **Freedman RS**. Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones. *Scand J Immunol* 37:413-424, 1993.
92. Fisk B, Flytzanes CN, Pollack M, **Freedman RS**, Wharton JT, and Ioannides CG. Characterization of T cell receptor V β repertoire in ovarian tumor reactive CD3+CD8+CD4-CTL lines, *Scan J Immunol* 1 40:591-600, 1994.
93. **Freedman RS**, Bowen JM, Delclos L, Edwards CL, Wallace S, Atkinson EN, Ioannides CG, Kasi LP, Scott W, Patenia R. Active intralymphatic immunotherapy of uterine cervical carcinoma with viral oncolysate: a pilot study. *Int J Gynecol Cancer* 4:101-110, 1994.

94. **Freedman RS**, Tomasovic B, Templin S, Atkinson EN, Kudelka A, Edwards CL, Platsoucas CD. Large scale expansion in IL-2 of tumor infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. *J Immunol Meth* 167:145-160, 1994.
95. Inskip PD, Eby NL, Cookfair D, **Freedman RS**, Richardson GS, Wactawski-Wende J, Hoover RN, Boice JD, Jr. Serum estrogen and androgen levels following treatment for cervical cancer. *Cancer Epidemiology, Biomarkers and Prevention* 3:37-45, 1994.
96. Vadhan-Raj S, Kudelka AP, Garrison L, Gano J, Edwards C, **Freedman RS**, and Kavanagh J. Effects of interleukin-1a on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. *J Clin Oncol* 12:707-714, 1994.
97. **Freedman RS**, Edwards CL, Kavanagh JJ, Kudelka A, Katz RL, Carrasco CH, Atkinson EN, Scott W, Tomasovic B, Templin S, Platsoucas CD. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor infiltrating lymphocytes, a pilot trial. *J Immunother* 16:198-210, 1994.
98. Chen P-F, **Freedman RS**, Chernajovsky Y, and Platsoucas CD. Amplification of immunoglobulin transcripts by the non-palindromic adaptor polymerase chain reaction (NPA-PCR). Nucleotide sequence analysis of two human monoclonal antibodies recognizing two cell surface antigens expressed in ovarian, cervix, breast, colon and other carcinomas. *Human Antibodies and Hybridomas* 5:131-142, 1994.
99. Coleman RC, **Freedman RS**, Keeney G, Burke TW, Eifel PJ, and Rutledge FN. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. *Gyn Onc* 55:29-35, 1994.
100. Kasi LP, Lamki L, Saranti S, Podoloff D, **Freedman RS**. Indium-111 labeled leukocytes in evaluation of active specific immunotherapy responses. *Int J Gyn Cancer* 5:226-232, 1995.
101. Kavanagh J, Tresukosol D, Edwards C, **Freedman R**, Gonzalez de leon C, Fishman A, Mante R, Hord M, and Kudelka A. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. *J Clin Oncol* 13:1584-1588, 1995.
102. Kavanagh JJ, Tresukosol D, Gonzalez De Leon C, Edwards CL, **Freedman RS**, Hord M, Howell E, Lenzi R, Krakoff IH, and Kudelka AP. Phase II study of prolonged oral etoposide in refractory ovarian cancer. *Int J Gynecol Cancer* 5:351-354, 1995.
103. Kavanagh JJ, Edwards CL, **Freedman RS**, Finnegan MB, Balat O, Tresukosol D, Burk K, Loechner S, Hord M, Franklin JL, Kudelka AP. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. *Gynecol Oncol* 58:106-109, 1995.
104. Nash MA, Platsoucas CD, Wong BY, Wong PMC, Cottler-Fox M, Otto E, and **Freedman RS**. Transduction of CD4⁺ and CD8⁺ rIL-2 expanded ovarian TIL-derived T-cell lines following infection with G1Na (neo^R) replication-deficient retroviral vector *Human Gene Therapy* 6:(11)1379-1389, 1995.

105. Quadri SM, Malik AB, Tang X-Z, Patenia R, **Freedman RS**, and Vriesendorp HM. Preclinical analysis of intraperitoneal administration of Indium-111 labeled human tumor reactive monoclonal IgM AC6C3-2B12. *Cancer Res* 55:5736-5742, 1995.
106. Soysal O, Balat O, Kudelka AP, Edwards CL, Aladag MA, Colak A, **Freedman RS**, Kavanagh JJ. Oncogenes and tumor suppressor gene therapy for cancer. (Review). *Cancer Molecular Biol* 2:591-596, 1995.
107. Lopez A, Tessadrelli A, Kudelka AP, Edwards CL, **Freedman RS**, Hord M, and Kavanagh JJ. Combination therapy with leuprolide acetate and tamoxifen in refractory ovarian cancer. *Int J Gynecol Cancer* 6:15-19, 1996.
108. Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, **Freedman RS**, Loyer E, Rusinkiewicz J, Gacrama P, Fueger R, Kavanagh JJ. Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. *Clin Cancer Res* 2:1285-1288, 1996.
109. Kudelka AP, Verschraegen CF, Levy T, Edwards CL, Fishman A, **Freedman RS**, Kaplan A, Kieback DG, Mante R, Ende K, Steger M and Kavanagh JJ. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. *Anti-Cancer Drugs* 7:398-401, 1996.
110. Tresukosol D, Kudelka P, Gonzales de Leon, Edwards CL, **Freedman RS**, Mante R, Hord MM, Kavanagh JJ. Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. *Eur J Gynaec Oncol* 17:188-191, 1996.
111. Piamsomboon S, Termrungruanglert W, Kudelka AP, Edwards CL, **Freedman RS**, Mountain CF, Delclos L, Aapro MS, DeCaro L, Bianca J, Verschraegen CF, and Kavanagh JJ. Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon- α and 13-cis-retinoic acid: report of two cases and review of the literature. *Anti Cancer Drugs* (case report) 7:800-804, 1996.
112. Vriesendorp HM, Quadri SM, Jaeckle KA, **Freedman RS**, Cromeens, DM. Proposal for translational analysis and development of clinical radiolabeled immunoglobulin therapy. *Radiother Oncol* 41:151-161, 1996.
113. Lin Y-C, Kudelka AP, Lawrence D, Verschraegen CF, Kavanagh JJ, Edwards CL, Mante R, **Freedman RS**. Transcatheter arterial embolization for the control of life-threatening pelvic hemorrhage in a patient with locally advanced cervix carcinoma. *Eur J Gynaec Oncol* XVII, 480-483, 1996.
114. Kooi S, Zhang H-Z, Patenia R, Edwards CL, Platsoucas CD, **Freedman RS**. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration *in vivo* and T-cell expansion *in vitro* in low concentrations of recombinant interleukin-2. *Cellular Immunol* 174:116-128, 1996.

115. **Freedman RS**, Platsoucas CD, Deisseroth AB. Use of a retroviral vector to study the trafficking patterns of purified ovarian tumor infiltrating lymphocytes (TIL) used in intraperitoneal adoptive immunotherapy of ovarian cancer patients. a pilot study. *Human Gene Ther* 7:1351-1365, 1996.
116. Quadri SM, Malik AB, Chu HB, **Freedman RS**, and Vriesendorp HM. Intraperitoneal indium-111 and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis. *J Nucl Med*, 9:1545-1551, 1996.
117. Verschraegen CF, Kudelka AP, Temrungruanglert W, de Leon CG, Edwards CL, **Freedman RS**, Kavanagh JJ, Vadhan-Raj S. Effects of interleukin-1 α on ovarian carcinoma in patients with recurrent disease. *Eur J Cancer* 32:1609-1611, 1996.
118. **Freedman RS**, Tortolero-Luna G, Pandey DK, Malpica A, Baker VV, Whittaker L, Johnson E, Mitchell MF. Gestational trophoblastic disease. *Gynecol Cancer Prevention*. 23:545-571, 1996.
119. Kudelka AP, Tresukosol D, Edwards CL, **Freedman RS**, Levenback CL, Chantarawiroj P, de Leon CG, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh, JJ. A phase II study of intravenous topotecan as a 2-day infusion for refractory epithelial ovarian carcinoma. *J Clin Oncol* 14:1552-1557, 1996.
120. **Freedman RS**, Gibbons JA, Giedlin M, Kudelka AP, Kavanagh JJ, Edwards CL, Carrasco CH, Nash MA, Platsoucas CD. Immunopharmacology and cytokine production of a low dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma. *J Immunother* 19:443-451, 1996.
121. Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, **Freedman RS**, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. *J Clin Oncol* 15:625-631, 1997.
122. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, **Freedman RS**, Kaplan AL, Kieback DG, Meyers CA, Jaeckle KA, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang JA, Gutterman JU, Kavanagh JJ. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. *Clin Cancer Res* 3:1501-1505, 1997.
123. Ferrandina G, Melichar B, Loercher A, Verschraegen CF, Kudelka AP, Edwards CL, Scambia G, Kavanagh JJ, Abbruzzese JL, and **Freedman RS**. Growth Inhibitory Effects Of Sodium-Phenylacetate (NSC #3039) On Ovarian Carcinoma Cells In Vitro. *Cancer Res* 57:4309-4315, 1997.
124. Kudelka AP, Winn R, Edwards CL, Downey EG, Greenberg H, Dakhil SR, **Freedman RS**, Lococo SJ, Umbreit J, Delmore JE, Arbuck S, Loyer E, Gacrama P, Fueger R, Kavanagh JJ. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. *Anti-Cancer Drugs* 8:765-661, 1997.

125. Borchardt PE, Quadri SM, **Freedman RS**, Vriesendorp HM. Intralesional radiolabeled human monoclonal IgM in human tumor xenografts. *Radiother Oncol* 44:283-293, 1997.
126. Kudelka AP, Siddik ZH, Tresukosol D, Edwards CL, **Freedman RS**, Madden TL, Rastogi R, Hord M, Kim EE, Tornos C, Mante R, Kavanagh JJ. A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma. *Anti-Cancer Drugs* 8:649-656, 1997.
127. Savary CA, Graziutti M, Melichar B, Przepiorka D, **Freedman RS**, Cowart RE, Cohen DM, Anaissie E, Woodside DG, McIntyre B, Pierson D, Pellis N, and Rex JH. Multidimensional flow cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients. *Cancer Immunol Immunother* 45:234-240, 1998.
128. Melichar B, Savary C, Kudelka AP, Verschraegen C, Kavanagh JJ, Edwards CL, Platsoucas CD, **Freedman RS**. Lineage negative HLA-DR⁺ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. *Clin Cancer Res* 4:799-809, 1998.
129. **Freedman RS**, Lenzi R, Kudelka AP, Lawrence DD, Rosenblum M, and Platsoucas CD. Intraperitoneal immunotherapy of peritoneal carcinomatosis. *Cytokines, Cellular & Molecular Therapy* 4:121-140, 1998.
130. Borchardt PE, Quadri SM, **Freedman RS**, Vriesendorp HM. Indium-111 and Yttrium-90 labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice. *J Nucl Med* 39:476-484, 1998.
131. Nash MA, Lenzi R, Edwards CL, Kavanagh JJ, Kudelka AP, Verschraegen CF, Platsoucas CD, and **Freedman RS**. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumor specimens, peritoneal exudate cells containing tumor, TIL-derived T-cell lines and established tumor cell lines. *Clin Exp Immunol* 112:172-180, 1998.
132. Kudelka AP, Hasenburg A, Verschraegen CF, Edwards CL, Meyers CA, Varma D, **Freedman RS**, Forman A, Conrad CA, Grove W, Grothey A, and Kavanagh JJ. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. *Anti-Cancer Drugs* 9:405-409, 1998.
133. Nash MA, Lenzi R, Platsoucas CD, and **Freedman RS**. RT-PCR quantitation of cytokine responses *in vivo* from specimens containing small numbers of cells during bioimmunotherapy. *J Immunol Meth* 219:169-179, 1998.
134. Melichar B, Ferrandina G, Verschraegen CF, Loercher A, Abbruzzese JL, and **Freedman RS**. Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. *Clin Cancer Res* 4:3069-3076, 1998.
135. Verschraegen CF, Kudelka AP, Loyer E, Edwards CL, **Freedman RS** and Kavanagh JJ. A phase II trial of high-dose hydroxyurea administered parenterally in patients with epithelial ovarian carcinoma refractory to platinum. *Int J Gynecol Cancer* 8:494-498, 1998.

136. Zavadova E, Loercher A, Verstovsek S, Verschraegen CF, Micksche M, **Freedman RS**. The role of macrophages in antitumor defense of patients with ovarian cancer. *Current Therapeutic Issues in Gynecologic Cancer* 13:135-144, 1999.
 137. Kudelka AP, Verschraegen CF, Shen Y, Gonzalez DeLeon C, Edwards CL, **Freedman RS**, Forman A, Gibbs HR, Mante R, Hord M, Canetta R, Krakoff I, Kavanagh JJ. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. *Int J Gynecol Cancer* 9:44-53, 1999.
 138. Gordinier ME, Zhang H-Z, Patenia R, Levy L, Atkinson EN, Nash MA, Katz RL, Platsoucas CD, and **Freedman RS**. Quantitative analysis of transforming growth factor-beta 1 and 2 on ovarian carcinoma. *Clin Cancer Res* 5:2498-2505, 1999.
1. Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, and **Freedman RS**. Identification of an IL-10 producing HLA-DR negative monocyte subset in the malignant ascites of patients with ovarian carcinoma which inhibits cytokine protein expression and proliferation of autologous T cells. *J Immunol* 163:6251-6260, 1999.
 2. Nash MA, Loercher AE, **Freedman RS**. *In vitro* growth inhibition of ovarian cancer cells by decorin: Synergism of action between decorin and carboplatin. *Cancer Res* 59:6192-6196, 1999.
 3. Nash MA, Ferrandina G, Gordinier M, Loercher A, and **Freedman RS**. The role of cytokines in both the normal and malignant ovary. *Endocrine-Related Cancer* 6:93-107, 1999.
 4. Melichar B, Nash MA, Lenzi R, Platsoucas CD, and **Freedman RS**. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on tumor infiltrating lymphocytes from patients with ovarian and other types of peritoneal carcinomatosis. *Clin Exp Immunol* 119:19-27, 2000.
 5. Borchardt PE, Quadri SM, **Freedman RS**, and Vriesendorp HM. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis. *Cancer Biother Radiopharmaceuticals* 15:53-64, 2000.
 6. Hu W, Wu W, Nash MA, **Freedman RS**, Kavanagh JJ, Verschraegen CF. Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines. *Anticancer Res* 20 (2A):729-733, 2000.
 7. **Freedman RS**, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash, M, Levy L, Atkinson EN, Zhang H-Z, Melichar B, Patenia R, Templin S, Scott W, and Platsoucas CD. Clinical and biological effects of intraperitoneal injections of recombinant interferon- γ and recombinant interleukin-2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. *Clin Cancer Res* 6:2268-2278, 2000.
 8. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Jr, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers, D, Bevers M, Burke T, **Freedman R**, Wolf J, and Champlin RE. Intensive-dose ifosfamide and

- 17.
18. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP, **Freedman RS**, Edwards CL, Gershenson D, Jones D, Ashby M, Kavanagh JJ. Recombinant human thrombopoietin attenuates carboplatin-Induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. *Annals of Int Med* 132(5):364-368, 2000.
- 19.
20. Hosing C, **Freedman RS**, McLaughlin P, Malpica A, Fornage B, Kudelka AP. Diffuse large B-cell non-Hodgkin's lymphoma presenting as a vaginal mass in a patient with a history of intestinal mucosa-associated lymphoid tissue (MALT) lymphoma (Report). *Am J Clin Oncol* 24:204-208, 2001.
- 21.
22. Donato M, Gershenson D, Burke T, Wharton JT, Bodurka-Bervers, D, Bervers, M, Wolf J, Levenback C, Bast RC, **Freedman R**, and Gajewski JL. High dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. *Gynecol Oncol* 82:420-426, 2001.
- 23.
24. Zavadoval E, Savary C, Templin S, Verschraegen C, and **Freedman RS**. Maturation of dendritic cells from ovarian cancer patients. *Cancer Chemother Pharmacol* 48:289-296, 2001.
- 25.
26. Azevedo P, Verschraegen CF, Kavanagh JJ, Kudelka AP, **Freedman RS**, Lu K, Deavers MT. Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report. *Eur J Gynaec Oncol* Vol 22 319-321, 2001.
- 27.
28. Manzullo E, Escalante C, Weiser MA, **Freedman RS**, Forman A. Case report : An elderly woman with an ovarian mass and myasthenia gravis. *Resident & Staff Physician* 47(1):55-61, Jan. 2001.
- 29.
30. Hu W, Verschraegen CF, Wu WG, Nash M, **Freedman RS**, Kudelka A, Kavanagh JJ. Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines. *Int J Gynecol Ca* 12(2) :202-207, 2002.
- 31.
32. Hu W, Wu W, Yeung SC, **Freedman RS**, Kavanagh JJ, Verschraegen CF. Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor. *Anticancer Res* 22 (2A):665-672, 2002.
- 33.
34. Nash MA, Deavers, MT, **Freedman RS**. The expression of decorin in human ovarian tumors. *Clinical Cancer Research* 8(6):1754-60, June 2002.
- 35.
36. Vadhan-Raj Saroj, Kavanagh John J, **Freedman RS**, Folloder Jody, Bueso-Ramos Carlos,
37. Verschraegen Claire F, Narvios Aida B, Connor Jerome, Hoots William K, Broemeling Lyle D, Lichtiger Benjamin. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised crossover study. *The Lancet* 359, 2145-2152, June 22, 2002.

- 38.
39. Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, and **Freedman RS**. Phase I study of intraperitoneal rhIL-12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies and mesothelioma. *Clinical Cancer Research* 8:3686-3695, December 2002.
- 40.
41. Gordonier M, Kudelka A, Kavanagh J, Wharton J, and **Freedman RS**. Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II study. *Int J Gynecol Cancer* 12:710-714, 2002.
- 42.
43. Verschraegen CF, Hu W, Du Y, Mendoze J, Early J, Deavers M, **Freedman RS**, Bast RC, Kudelka AP, Kavanagh JJ, Giovanella BC. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic mullerian cancers. *Clin Can Research* 9:845-852, 2003.
- 44.
45. Melichar B, Lenzi R, Rosenblum M, Kudelka AP, Kavanagh JJ, Melicharova K, Templin S, Garcia ME, Abbruzzese JL, **Freedman RS**. Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12. *J of Immunother* 26(3): 270-276, 2003.
- 46.
47. Melichar B, Savary CA, Patenia R, Templin S, Melicharova K, and **Freedman RS**. Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. *Int J Gyn Ca* 13:435-443, 2003.
- 48.
49. Platsoucas CD, Fincke JE, Pappas J, Jung W-J, Heckel M, Schwarting R, Magira E, Monos D, and **Freedman RS**. Immune responses to human tumors: development of tumor vaccines. *Anticancer Res* 23: 1969-1996, 2003.
- 50.
51. Melichar B, Hu W, Patenia R, Melicharova K, Gallardo ST, **Freedman R**. rIFN γ -mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. *J Translational Med* 1:5, 2003.
- 52.
53. Hu W, Wu WG, Verschraegen CF, Chen L, Mao L, Yeung SCJ, Kudelka AP, **Freedman RS**, Kavanagh JJ. Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. *Proteomics* 3:1904-1911, 2003.
- 54.
55. **Freedman RS**, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, Kavanagh JJ, Hicks ME, Levy LB, Folloder J, Garcia ME. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. *Clin Can Research* 9:5228-5237, 2003.
- 56.
57. Borchardt PE, Vriesendorp HM, **Freedman RS**, Quadri SM. Intralesional radioimmunotherapy with yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts. *Cancer Biother Radiopharm* 19(1):43-51, 2004.
- 58.
59. Melichar B, Konopleva M, Hu W, Melicharova K, Andreeff M, **Freedman RS**. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic

- acid on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor- γ expression. *Gynecol Onc* 93 (1):149-154, 2004.
- 60.
 61. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, **Freedman RS**, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. *Bone Marrow Transplant* 33(12):1219-1224, 2004.
 - 62.
 63. Wang E, Panelli MC, Zavaglia K, Mandruzzato S, Hu N, Taylor PR, Seliger B, Zanovello P, **Freedman RS**, Marincola FM. Melanoma-restricted genes. *J Translational Med* 2:34, 2004.
 - 64.
 65. Wang E, Ngalame Y, Panelli M, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CS, Kobayashi R, **Freedman RS**, Marincola FM. Peritoneal and sub-peritoneal stroma may facilitate regional spread of ovarian cancer. *Clin Can Research* 11 (1): 113-121, 2005.
 - 66.
 67. See HT, **Freedman RS**, Kudelka AP, Burke TW, Gershenson DM, Tangjitgamol S, Kavanagh JJ. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. *Int J Gynecol Ca* 15 (2):209-216, 2005.
 - 68.
 69. Hu W, Kavanagh JJ, Deavers M, Johnston DA, **Freedman RS**, Verschraegen CF, Sen S. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. *Oncol Res* 15(1):49-57, 2005.
 - 70.
 71. Monos D, Pappas J, Magira EE, Gaughan J, Aplenc R, Sakkas L, **Freedman RS**, Reveille JC, Platsoucas CD. Identification of HLA-DQ α 1 residues associated with susceptibility and protection to epithelial ovarian cancer. *Human Immunology* 66: 554-562, 2005.
 - 72.
 73. Wang X, Wang E, Kavanagh JJ, **Freedman RS**. Ovarian cancer, the coagulation pathway, and inflammation. *J Translational Med* 3:25, 2005.
 - 74.
 75. Pappas J, Jung W-J, Barda AK, Lin WL, Fincke JE, Radu M, Gaughan J, Helm CW, Hernandez E, **Freedman RS**, Platsoucas CD. Substantial proportions of identical β -chain t-cell receptor (TCR) transcripts are present in epithelial ovarian carcinoma tumors. *Cellular Immunology* 234(2):81-101, 2005.
 - 76.
 77. **Freedman RS**. Non-Cytotoxic therapeutics: past and future. *Oncologie* 7:564-568, 2005.
 - 78.
 79. Gordon IO and **Freedman RS**. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. *Clin Ca Res* 12(5):1515-1524, 2006.
 - 80.
 81. Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B, **Freedman RS**, Taylor PR, Hu N, Zanovello P, Marincola FM, Wang E. Common Cancer Biomarkers for Colon, Melanoma, Ovarian and Esophageal Tumors. *Ca Res* 66 (6):2953-2961, 2006.
 - 82.

83. Melichar B, Solichova D, and **Freedman RS**. Neopterin as an indicator of immune activation and prognosis in patients with gynecologic malignancies. *Int. J. of Gyn Can* 16 (1):240-252, 2006.
- 84.
85. Apte SM, Vadhan-Raj S, Cohen L, Bassett RS, Gordon IO, Levenback CF, Ramirez PT, Gallardo ST, Patenia RS, Garcia ME, Iyer RB, **Freedman RS**. Cytokines, GM-CSF and IFN γ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. *J Trans Med* 4:16, 2006.
- 86.
87. Wang X, Deavers M, Patenia R, Bassett RL, Mueller P, Ma Q, Wang E, **Freedman RS**. Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease. *J Trans Med* 4:30, 2006.
- 88.
89. Wang X, Fu S, **Freedman RS**, Liu J, Kavanagh JJ. Immunobiology of gestational trophoblastic diseases. *Int J Gynecol Cancer* 16:1500-1515, 2006.
- 90.
91. Melichar B, Patenia R, Gallardo S, Melicharova K, Hu W, **Freedman RS**. Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. *Gynecologic Oncology* 104:707-713, 2007.
- 92.
93. Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, **Freedman RS**, Klostergaard J. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44 (+) human ovarian carcinoma xenografts. *Neoplasia* 9:479-486, 2007.
- 94.
95. **Freedman RS**, Wang E, Voiculescu S, Patenia R, Bassett RL, Deavers M, Marincola FM, Yang P, Newman RA. Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. *Clin Ca Res* 13(19):5736-5744, 2007.
- 96.
97. Lenzi R, Edwards R, June CH, Seiden M, Garcia ME, Rosenblum M, **Freedman RS**. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. *J Trans Med.* 5:66, 2007.
- 98.
99. Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, **Freedman RS**, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LB, Pazdur R. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR public workshop. *Gyn Onc* 107:173-176, 2007.
- 100.
101. **Freedman RS**, Ma Q, Wang E, Gallardo ST, Gordon IO, Shin JW, Jin P, Stroncek D, Marincola FM. Migration deficit in monocyte-macrophages in human ovarian cancer. *Cancer Immunology, Immunotherapy* 57:635-645, 2008.
- 102.
103. Cole ME, Broaddus R, Thaker P, Landen C, **Freedman RS**. Placental-site trophoblastic tumors: a case of resistant pulmonary metastasis. *Nat Clin Pract Oncol* 05(3):171-175, 2008.
- 104.
105. Kobayashi R, Deavers M, Patenia R, Rice-Stitt T, Halbe J, Gallardo S, **Freedman RS**. 14-3-3 zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients. *Cancer Immunology, Immunotherapy* 58:247-258, 2009.

- 106.
107. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RS, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, **Freedman RS**. A phase II study of GM-CSF and rIFN- γ 1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. *Gyn Onc*. 113: 210-215, 2009.
108. Pappas J, Wolfson AD, Jung WJ, Oleszak EL, Helm CW, **Freedman RS**, Tsygankov AY, and Platsoucas CD. Differential Expression of CD3z message and protein in tumor infiltrating lymphocytes from solid tumor specimens and malignant ascites from patients with ovarian carcinoma. *Anticancer Research* : 29:4673-4682(2009)
109. Teoh D, **Freedman R**, Soliman PT, Nearly 30 years of treatment for recurrent granulose cell tumor of the ovary: A case report and review of the literature. *Case Reports in Oncology*3:14-18, 2010
110. Telesca D, Mueller P, Parmigiani G, **Freedman R** “Modelling Dependent Gene Expression, Harvard University Working Paper Series. Working Paper 114 (February 2010)
- 111.
- 112.
- 113.
- b. Invited Articles:**
114. **Freedman RS**. Methotrexate in gestational trophoblastic disease. *Cancer Bulletin* 33(2):63-66, 1981.
115. **Freedman RS**. Intraperitoneal immunotherapy in a patient with ovarian carcinoma. *Cancer Bulletin* 36(5):250-251, 1984.
116. **Freedman RS**. Editorial Commentary: Diagnosis and treatment of ovarian cancer. *Oncology Overview*, International Cancer Research Data Bank Program, National Cancer Institute. November 1984.
117. **Freedman RS**. Gestational trophoblastic disease. *Cancer Bulletin* 38(6):290-293, 1986.
118. **Freedman RS**. Epithelial ovarian cancer. *Oncology Update* 5:1-13, 1988.
119. **Freedman RS**. Oncology overview on gestational trophoblastic disease. *Oncology Overview*, International Cancer Research Data Bank Program, National Cancer Institute, September, 1988.
120. **Freedman RS**, and Ioannides CG. Biological response modifiers in the treatment of gynecologic malignancies. *Cancer Bulletin* 42:98-105, 1990.
121. **Freedman RS**. Biologic response modifiers in gynecologic malignancies. *Cancer Bulletin* 43:139-145, 1991.
122. Platsoucas CD, and **Freedman RS**. Tumor infiltrating lymphocytes (TIL) in gene therapy. *Cancer Bulletin* 45:118-124, 1993.

123. **Freedman RS**, Lenzi R, Kudelka AP, Rosenblum M, Platsoucas CD. Intraperitoneal immunotherapy of peritoneal carcinomatosis. *Cytokines, Cellular and Molecular Therapy* 4:121-140, 1998.
124. Gordinier ME, **Freedman RS**. Conservative management of endometrial cancer in the premenopausal woman. *M.D. Anderson Oncology (Case Reports & Review)* (1998).
125. **Freedman RS**, and Brown B. Adjuvant Therapy. S. Eva Singletary (ed) in: *Breast Diseases: A Year Book Quarterly* 8:373-374, 1998.
126. Butts C, **Freedman RS**. Vaccines for ovarian carcinoma. *Cancer Control* 6:335-342, 1999.
127. Nash M, Ferrandina G, Gordinier M, Loercher A, and **Freedman RS**. The role of cytokines in both the normal and malignant ovary. *Endocrine-Related Cancer (review article)* 6:93-107, 1999.
128. Melichar B & **Freedman RS**. Immunology of the peritoneal cavity: relevance for host-tumor relation. *Int Jnl of Gynecolog Cancer (review article)* 12:3-17, 2002.
129. Hwu P & **Freedman RS**, The immunotherapy of ovarian cancer. *Jrnl of Immunotherapy* 25(3):189-201, 2002.
130. **Freedman RS**, Deavers M, Liu J, Wang E. Peritoneal inflammation – a microenvironment for epithelial ovarian cancer (EOC). *J Translational Med* 2:23, 2004.
- 131.
132. Dixon DO, **Freedman RS**, Herson J, Hughes M, Kim K, Silverman MH, Tangen CM. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees. *Clinical Trials* 3:314-319, 2006.
133. **Freedman Ralph S**. Editorial Comment : Staging early ovarian cancer : impact on treatment decisions. *European Journal of Cancer*,46; 856-8 (2010)
134. Behrouz Zand and **Ralph S Freedman**. Staging Early Ovarian Cancer. *Encyclopedia of Cancer*. Springer Verlag, in press (2011)

c. Editorials
Editorial Abstracts

1. **Freedman RS** (ed). Female Genital Tract, in: 1987 Year Book of Cancer, pages 275; 177; 178; 183; 184; 185.
2. **Freedman RS** (ed). Female Genital Tract, In: 1988 Year Book of Cancer, pages 174; 175, 176; 178; 179; 180; 182; 184; 187.

3. **Freedman Ralph S.** could a clinical trial be right move for you? Houston Chronicle , Viepoints, Outlook September 18, 2010

d. Other Articles
N/A

e. Abstracts

1. Lenzi R, Kudelka AP, Verschraegen C, Nash M, Loercher A, Zhang H-Z, Katz RL, Abbruzzese JL, Kavanagh JJ, Platsoucas CD, and **Freedman RS.** Intraperitoneal (IP) bioimmunologic responses in patients with ovarian and gastrointestinal cancers at a low toxicity dosing schedule of IP recombinant interleukin-12 (rhIL-12). Proceed of AACR 40: A3778, pp 573, 1999.
2. Nash M, Lenzi R, Platsoucas CD, and **Freedman RS.** RT-PCR quantitation of cytokine responses *in vivo* from specimens containing small numbers of cells during bioimmunotherapy. Proceed of AACR 40:A 536, pp 80, 1999.
3. Loercher A, Kavanagh JJ, Verschraegen C, Platsoucas CD, and **Freedman RS.** Induction of IL10 secreting monocytes using peripheral blood mononuclear leukocytes of patients with epithelial ovarian cancer (EOC) cultured in the presence of rGM-CSF and rIL-2. Proceed of AACR 40: A3776, pp 573, 1999.
4. Melichar B, Nash M, Lenzi R, Platsoucas CD, and **Freedman RS.** Coexpression of B7 costimulatory molecules and CD28 and CTLA-4 on tumor infiltrating lymphocytes (TIL) from patients with peritoneal carcinomatosis. Proceed of AACR 40: A3775, pp 574, 1999.
5. **Freedman RS,** Platsoucas CD, Schlom J, Salazar E, Melichar B, Nash M, Kudelka AP, Verschraegen C, Kavanagh J, Abbruzzese JL. Infection of fresh epithelial ovarian carcinoma (EOC) cells with a canary pox construct ALVAC-hB7.1 after *in vitro* treatment with rIFN- γ and early clinical results. Proceed of AACR 40: A3792, pp 575, 1999.
6. Kim YM, Zavadova E, Loercher A, **Freedman RS.** Comparison of media conditions to expand TIL-derived T-cell lines from patients with peritoneal carcinomatosis including serum free, rIFN- γ and polyezyme preparation. Proceed of AACR 40: A1220, pp 183, 1999.
7. Kudelka AP, **Freedman RS,** Kavanagh JJ, Verschraegen C, Scott W, Edwards CL, Nash M, Levy L, Atkinson EN, and Platsoucas CD. Clinical and biologic effects of intraperitoneal (IP) injections of recombinant interferon-gamma (rIFN- γ) and recombinant interleukin-2 (rIL-2) \pm TIL in patients with ovarian or peritoneal carcinoma. Proceed of AACR 40: A3774, pp 572, 1999.
8. Lenzi R, Kudelka AP, Verschraegen C, Nash M, Loercher A, Zhang HZ, Katz RL, Abbruzzese JL, Kavanagh JJ, Platsoucas CD, **Freedman RS.** Recombinant human interleukin-12 (rhIL-12) in patients with ovarian and gastrointestinal cancers. Evidence of biological activity and lack of significant toxicity with low-dose intraperitoneal (IP) administration. Proceed of ASCO 18: A1721, pp 446, 1999.

9. Donato M, Gershenson D, Wharton JT, Aleman A, Ippoliti C, Bodurka D, Levenback C, Bevers M, Wolf J, **Freedman R**, Gajwesi J, Bast R, and Champlin RE. Phase I study of high-dose topotecan and alkylating agents for advanced ovarian cancer. Proceed of ASCO 18:164, pp 44, 1999.
10. Steger M, Kudelka AP, **Freedman RS**, Verschraegen C, Hu, W, Du Y, Kavanagh JJ. Phase II study of SB-75 a LHRH antagonist in patients with ovarian cancer. Proceed of ASCO 18: A1398, pp 362, 1999.
11. Hu W, Wu W, Kuang J, Mendoza J, Kudelka AP, **Freedman RS**, Kavanagh JJ, Sen S, Zhou HY, Verschraegen C. Overexpression of STK15/BTAK correlates with increased malignancy of ovarian cancer cell lines. Proceed of AACR 40: A2458, pp 371, 1999.
12. Pappas J, Reveille JD, Gaughan J, Sakkas LI, **Freedman RS**, Platsoucas CD. HLA-DRB1, -DQA1 and -DQB1 alleles in ovarian carcinoma. Proceed of AACR 40: A3283, pp. 497, 1999.
13. Verschraegen C, Hu W, Mendoza J, Du Y, Kudelka AP, **Freedman RS**, Kavanagh JJ, Giovanella B. Characterization of twenty-three Müllerian cell lines derived from primary ovarian cancers. Proceed of AACR 40: A3291, pp. 491, 1999.
14. Pappas J, Lin WL, Helm CW, B, **Freedman RS**, Platsoucas CD. Substantial proportions of identical T cell receptor transcripts in ovarian tumor infiltrating lymphocytes. Proceed of AACR 40 A3294, pp. 499, 1999.
15. Hu W, Verschraegen C, Wu WG, Mendoza J, **Freedman RS**, Kavanagh JJ, Nash MA. Resistance to TGF- β in cell lines derived from ovarian cancers is related to low expression of DPC-4. Proceed of AACR 40: A3707, pp 562, 1999.
16. Kudelka AP, Verschraegen C, Edwards CL, **Freedman RS**, Plunkett WK, Nicol S, Kavanagh JJ. A preliminary report of a phase II study of gemcitabine in women with platinum refractory Müllerian (ovarian, fallopian tube and primary peritoneal) carcinomas. Proceed of ASCO 18:A1457, pp 377, 1999.
17. Lenzi R, Kudelka A, Verschraegen C, Nash M, Loercher A, Zhang HZ, Katz RL, Abbruzzese JL, Kavanagh JJ, Platsoucas CD, Rosenblum M, **Freedman RS**. Intraperitoneal administration of human recombinant interleukin-12 (rhIL-12) for the treatment of ovarian and GI cancer patients with progressive disease after standard chemotherapy (T97-0034). Molecular Targets and Cancer Therapeutics, sponsored by AACR-NCI-EORTC, Washington, D.C., Nov. 16-29, 1999.
18. Lee, LYL, Loercher AE, Lenzi R, Kudelka A, Platsoucas CD, **Freedman RS**. *In vitro* effects of rhIL-12 on cytokine production by peripheral blood mononuclear cells and purified T cells from normal subjects and patients with epithelial ovarian cancer. Proceed of AACR 41:A1234, pp 193, 2000.

19. Loercher AE, Kavanagh JJ, Kudelka A, Verschraegen C, and **Freedman RS**. *In vitro* differentiation of suppressor monocytes to immunostimulatory cells by the addition of TNF- α and IFN- γ . Proceed of AACR 41:A1233, pp 193, 2000.
20. Zhang W, Lenzi R, Platsoucas CD, **Freedman RS**, Abbruzzese JL, and Rosenblum M. Clinical pharmacology studies of rhIL-12 administered by the IP route. Proceed of AACR 41:A1238, pp 194, 2000.
21. Verschraegen CF, Hu W, Wu W, Mendoza J, **Freedman RS**. The effect of growth inhibition by ALRT 1550 alone and in combination with interferon- γ . Proceed of AACR:A1746, pp.274, 2000.
22. Butts C, Templin S, Peng C, **Freedman RS**. IL-12 production by dendritic cells in the peritoneal cavity of patients with epithelial ovarian cancer following in vitro treatment with GM-CSF and IL-4. Proceed of AACR 41:A3946, pp 621, 2000.
23. Nash MA, Bhala R, **Freedman RS**. Studies on the effect of decorin on the growth of ovarian cancer cells. Proceed of AACR 41:A5467, pp 861, 2000.
24. Ferrandina GM, Raspaglio G, Ranelletti FO, V Morizio C, Ferlini C, Filippini F, D'Inglullo S, Mancuso S, **Freedman RS**, and Scambia G. Role of mitogen-activated kinases (MAPK) and effects of specific MAPK-inhibitors on the EGF-promoted biological activities in HEP2 human laryngeal cancer cells. Proceed of AACR 41:A2563, pp 403, 2000.
25. Zavadova E, Savary C, and **Freedman RS**. Maturation of dendritic cells (DC) from ovarian cancer patients. AACR-NCI-EORTC Internat. Conf. Wash, D.C., Nov 16-19, 1999 Clin Cancer Res (supp)5:A152.
26. Donato ML, Gershenson DM, Ippoliti C, Wharton JT, Bevers MW, Bodurka-Bevers DC, Levenback CF, Wolf JK, **Freedman RS**, Bast RC, Burke TW, Champlin RE. Topotecan in combination with cyclophosphamide and melphalan for stem cell transplantation: Results of a large phase I trial in advanced ovarian cancer. Proceed of AACR 41:A192, pp 50, 2000.
27. Vadhan-Raj S, Kavanagh JJ, **Freedman RS**, Folloder J, Currie LM, Bueso-Ramos CE, Hoots WK, Connor J, Verschraegen C, Wolf JK, Wharton J, Lichtiger B. Successful transfusions of recombinant human Thrombopoietin (rhTPO)-derived autologous platelets cryopreserved with tromobosol and 2% DMSO to support carboplatin-associated severe thrombocytopenia. Proc of ASCO 20:8a, 2001.
28. Verschraegen C, Hu W, **Freedman RS**, Kudelka AP, Kavanagh JJ, Yeung SJ. Growth inhibitory effect on FTI alone and in combination with Quercetin on ovarian cancer cell lines. Proc of AACR 42:2623, 2001.
29. Hu W, Wu W, Yeung SJ, Kavanagh JJ, **Freedman RS**, Mao L, Verschraegen C. Increased expression of HSP 70 in ovarian cancer cell line following treatment with FTI. Proc of AACR 42:2627, 2001.

30. Donato ML, Aleman AS, Gershenson DM, Wharton JT, Bast RC Jr, Burke TW, Bodurka-Bever D, Bevers MW, Levenback CF, Wolf JK, **Freedman RS**, Cooke S, Ippoliti C, Brewer M, Gajewski JL, Champlin RE. Long-term results of 102 patients with advanced ovarian cancer treated with high-dose chemotherapy. Proc of ASCO 20:204a, 2001.
31. Hu W, Verschraegen CF, Wu W, Lu K, Liu J, Yung MS, Kudelka AP, **Freedman R**, Kavanagh JJ. Differential protein profile analysis of sera from normal donors and ovarian cancer patients. Proc of AACR 43:37, 2002.
32. Melichar B, Patenia R, Templin S, Melicharová K, **Freedman R**. Effects on epithelial ovarian carcinoma cells and monocyte cytotoxicity induced by recombinant human soluble CD40L ligand trimer (rhuCD40L) \pm recombinant interferon gamma (rIFN- γ). Proc of AACR 43:442, 2002.
33. Hu W, Verschraegen CF, Wu W, **Freedman R**, Kudelka AP, Kavanagh JJ, Yeung, J. Enhanced apoptotic effect of heat shock protein inhibitor in combination with farnesyl transferase inhibitors (FTI) on ovarian and mesothelioma cancer cells. Proc of AACR 43:600, 2002.
34. Butts CL, Savary CA, Vadhan-Raj, S, **Freedman RS**. IL-12 and IL-10 production in dendritic cell cultures from peritoneal exudate cells (PEC) and peripheral blood mononuclear cells (PBMCs) of patients with epithelial ovarian cancer following treatment in vitro with soluble CD40 ligand (CD40L). Proc of AACR 43:973, 2002.
35. Melichar B, Lenzi R, Rosenblum M, Verschraegen C, Kudelka A, Kavanagh J, Melicharova K, Templin S, Garcia M, Abbruzzese J, **Freedman R**. Peritoneal fluid (PF) neopterin, nitrate and tryptophan after intraperitoneal (IP) administration of interleukin-12 (IL-12). Proc of ASCO 21 (1):17a, 2002.
36. **Freedman RS**, Vadhan-Raj S, Verschraegen C, Kavanagh J, Levy L, Atkinson EN, Kudelka AP, Butts C, Folloder J, Garcia M, Caron D. Pilot study of Flt3 ligand in patients with peritoneal carcinomatosis. Proceedings of ASCO 21 (1):20a, 2002.
37. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary C, **Freedman RS**, Marincola FM. Peritoneal and sub-peritoneal stroma may facilitate regional spread of ovarian cancer. Proc of AACR 45:1778a, 2004
38. Okrent IA, **Freedman RS**. Monocyte and Macrophage (MO/MA) Subpopulations in Epithelial Ovarian Cancer (EOC). Proc of AACR 45:1259a, 2004
39. Hu W, Chen L, Wu W, Bolanos-Clark M, Verschraegen C, Yeung S-C, Kudelka A, **Freedman RS**, Kavanagh JJ. Enhancing tumor killing with the combined treatment of Manumycin and Paclitaxel-resistant ovarian cancer cells. Proc of AACR 2004
40. Gordon IO, **Freedman RS**. Monocytes and macrophages in epithelial ovarian cancer are deficient Fc γ R mediated functions. Proc of AACR 46:2440a, 2005

41. Hu W, Kavanagh JJ, Deavers M, Fu S, Johnson D, **Freedman RS**, Verschraegen C, Sen S. Frequent over-expression of STK15/AURORA-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Proc of AACR 46:5742a, 2005.
42. Apte S, Vadhan-Raj S, Cohen L, Yang Y, Levenback C, Ramirez PT, Iyer R, Gallardo S, Garcia M, **Freedman RS**. Hemapoietic, immunomodulatory, antitumor, and toxicity profiles of sequential GM-CSF and IFN γ 1b biotherapy and carboplatin in recurrent ovarian carcinoma. Proc of ASCO 23:5053a, 2005.
43. Escalante CP, Oh JH, Baum DD, Mante M, Zalpour A, Spivey S, Stewart C, Ensor J, Grover T, **Freedman RS**. Immediate adverse reactions to chemotherapy: experience of a large ambulatory treatment center. Proc. Of ASCO 24:8558a, 2006.

f. Book Chapters

1. **Freedman RS**, Bowen JM, Herson J, Wharton JT, Rutledge FN. Experience in TFD in advanced gynecological cancer and two nongynecological sarcomas. *Immune Regulators in Transfer Factor*. (Amanullah Khan and Charles Kirkpatrick, eds). Academic Press, Inc. pp. 597-604, 1979.
2. **Freedman RS**. Recent immunological advances affecting the management of ovarian cancer. *Clinical Obstetrics and Gynecology* (Guest eds. EJ Quilligan, JT Wharton) J.B. Lippincott Company, Publishers, Vol 28, No. 4, pp. 849-867, 1985.
3. **Freedman RS**. The control of chemotherapy-induced nausea and emesis. Monograph. The Upjohn Company, 1986.
4. Lotzová E, Savary CA, **Freedman RS**, Bowen JM. NK cell antitumor activity of patients with ovarian carcinoma. Induction of cytotoxicity by viral oncolysates and interleukin-2. *Gynecologic Cancer: Diagnosis and Treatment Strategies*, (FN Rutledge, **RS Freedman**, and DM Gershenson, eds.). Proceedings of the University of Texas M. D. Anderson Cancer Center's 29th Annual Clinical Conference. University of Texas Press, 1987.
5. Jones LA, Press MF, Holt JA, Gallager HS, **Freedman RS**, Edwards CL. Comparison of immunologic and steroid-binding assays for estrogen receptors in human ovarian carcinomas. In: Rutledge FN, Freedman RS, Gershenson DM (eds.). *Gynecologic Cancer: Diagnosis and Treatment Strategies*. Austin: University of Texas Press, 1987, pp. 111-121.
6. Lotzová E, Savary CA, **Freedman RS**, Bowen JM. Natural killer cell antitumor activity in patients with ovarian carcinoma: Induction of cytotoxicity by viral oncolysates and interleukin-2. In: Rutledge FN, **Freedman RS**, Gershenson DM (eds.). *Gynecology Cancer: Diagnosis and treatment Strategies*. Austin: University of Texas Press 1987, pp. 123-126.
7. **Freedman RS**, Bowen JM, Lotzová E, Edwards CL, Lewis E, Katz RL. Virus augmentation as a biologic-modifier approach: Experience with intracavitary virus-augmentation therapy. In:

- Rutledge FN, Freedman RS, Gershenson DM (eds). *Gynecologic Cancer: Diagnosis and Treatment Strategies*. Austin: University of Texas Press, 1987, pp. 137-157.
8. Fritsche HA, **Freedman RS**, Liu FJ, Cox CJ. Tumor markers for gynecologic cancers. In: Rutledge FN, **Freedman RS**, Gershenson DM (eds). *Gynecologic Cancer: Diagnosis and Treatment Strategies*. Austin: University of Texas Press, 1987, pp. 385-396.
 9. **Freedman RS**. Conventional treatment results in epithelial ovarian cancer. In: Autologous Bone Marrow Transplantation, ed. by Dicke KA, and Keating A. *Cancer Treatment Research Education Fund*, 1993, pp. 183-191.
 10. **Freedman RS**, Edwards CL, Bowen JM, Tomasovic B, Patenia R, and Scott W. Regional clinical responses following intraperitoneal injection of allogeneic viral oncolysate in patients with epithelial ovarian carcinoma (Heidelberg, Germany). In: Bastert G, Wallwiener D, Keckstein J, eds. 2nd European Congress in Gynaecological Endoscopy and New Surgical Techniques. Bologna, Italy: Monduzzi Editore, 1994: 35-42.
 11. **Freedman RS**, Platsoucas CD. Immunotherapy for peritoneal ovarian carcinoma metastasis using *ex vivo* expanded tumor infiltrating lymphocytes (TIL). Paul H. Sugarbaker (ed). In: Peritoneal carcinomatosis, Principles of Management. Kluwer Academic Publishers, Norwell, MA Vol 2;115-146, 1996.
 12. Page RD, Kavanagh JJ, Edwards CL, Kudelka AP, **Freedman RS**, and Kavanagh JJ. Gestational Trophoblastic Tumors. In: Medical Oncology: A Comprehensive Review. Pazdur R (ed), PRR, Huntington NY, pp 377-391, 1996.
 13. **Freedman RS**, Kudelka AP, Verschraegen CF, Platsoucas, CD. Progress Toward Tumor Specific Immunity in Carcinomas of the Ovary and Breast. J. Kavanagh, S. Eva Singletary, Nina Einhorn and A. Denny DePetrillo (ed). In: *Cancer in Women*. Blackwell Science, Inc., Cambridge, MA 02142, pp. 30-53, 1998.
 14. Kudelka AP, Page, RD **Freedman RS**, and Kavanagh JJ. Gestational trophoblastic tumors. In: *Cancer Management: A multidisciplinary approach*. Fifth & sixth editions. Chapter 23, 1996.
 15. Ramirez PT, **Freedman RS**. Gynecologic Problems in Patients with Breast Cancer, Chapter 14. In: M.D. Anderson Cancer Care Series, Breast Cancer. Springer-Verlag, New York. pp 382-405, 2001.
 16. Kudelka AP, **Freedman, RS**, and Kavanagh JJ. Gestational trophoblastic tumors, Chapter 24. In: *Cancer Management: a multidisciplinary approach*. Eighth edition, 2004.
 17. **Freedman, RS**. Intraperitoneal therapy in ovarian cancer: immunotherapy, Chapter 4. In: *Intraperitoneal Cancer Therapy*. CW Helm and Robert Edwards (eds). Humana Press, Inc., Totowa, NJ, May 2007.
- g. Books (edited and written)**

N/A

h. Letters to the Editor

Kudelka AP, Lenzi R, Atkinson EN, Levy LB, and **Freedman RS**. Is ascitic fluid interleukin-12 an independent prognostic factor in ovarian cancer? The necessity of correction milligram *P* values for multiple comparisons. *J Clin Oncol* 16:3208, 1998.

i. Manuals, Teaching Aids, Other Publications

1. Gynecology Manual (contribution).
2. Video Tape: "Current Trends in Anti-emetic Therapy". Produced by the Upjohn International Inc., Kalamazoo MI. Filmed by M.D. Anderson Biomedical Communications Department, May 8, 1986.
3. Lecture Series on Immunology (given annually to Fellows, Residents).
4. "Journey to Health: Mind – Body – Spirit" Educational Video Series, "Coping with Cancer" segment participant. Produced by Public Education Office (MDACC) and Dallas County Community College District, September 2003

j. Other

Monographs

1. **Freedman RS**. The control of chemotherapy-induced nausea and emesis. Current Hospital Topics, Upjohn, 1986.
2. Bitran JD, **Freedman RS**, O'Dwyer PJ, and Zincke H: Expanding clinical applications of thiotepa. *Cancer Chemotherapy Monographs*, NCM Publication, 1989.
3. Hunt KK, Robb GL, Strom EA, Ueno NT, eds. *Breast Cancer*. New York, NY: Springer-Verlag, Inc; 2001. Buzdar AU, **Freedman RS**, Series Editors. *The M. D. Anderson Cancer Care Series*; Vol. 1.
4. Fossella FV, Komaki R, Putnam, JB Jr., eds. *Lung Cancer*. New York, NY: Springer-Verlag, Inc; 2003. Buzdar AU, **Freedman RS**, Series Editors. *The M.D. Anderson Cancer Care Series*; Vol. 2.
5. Ajani JA, Curley SA, Janjan NA, Lynch PM, eds. *Gastrointestinal Cancer*. New York: Springer Science+Business Media, Inc.; 2005. Buzdar AU, **Freedman RS**, eds. *M.D. Anderson Cancer Care Series*; Vol. 3.
6. Chan KW, Raney RB Jr., eds. *Pediatric Oncology*. New York: Springer Science + Business Media, Inc., 2005. Buzdar AU, **Freedman RS**, Series Eds. *M.D. Anderson Cancer Care Series*; Vol. 4
7. Eifel PJ, Gershenson DM, Kavanagh JJ, Siva EG, eds. *Gynecologic Cancer* New York: Springer Science+Business Media, Inc.; 2006. Buzdar AU, **Freedman RS**, Series Eds. *M.D. Anderson Cancer Care Series*; Vol. 5

8. DeMonte F, Gilbert MR, Mahajan A, McCutcheon IE, eds., *Tumors of the Brain and Spine*. New York: Springer Science+Business Media Inc.; 2007. Buzdar AU, **Freedman RS**, Series Eds. *M. D. Anderson Cancer Care Series; Vol 6*
9. Hunt KK, Robb GL, Strom E.A, Ueno NT, eds., *Breast Cancer (second edition)* New York: Springer Science+Business Media Inc.; 2008. Buzdar AU, **Freedman RS**, Series Eds. *The MD Anderson Cancer Care Series; Vol 7*

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

1. Editor, Cancergram for Gynecologic Tumors, 1978
2. Consulting Reviewer, *Gynecology Tumors*, National Cancer Institute, International Cancer Research Data Bank (ICRDB)
3. Section Chief, Female Genital Tract, in: *Year Book of Cancer*, Editor-in-Chief Robert C. Hickey, M.D., Managing Editor, Diane S. Rivera, Publishers, Year Book Medical Publishers, Chicago, Illinois, 1986/1987.
4. Editorial Staff, *Yearbook of Cancer*, U.T. M.DACC, 1986-1988.
5. Section Chief, Gynecology, *Yearbook of Gynecology*, 1986-88.
6. Series Editor, Monograph Series entitled “*Multidisciplinary Care of the Cancer Patient*” Springer-Verlag, New York, NY, 2000/2001.
7. Editorial Board, *International Journal of Gynecological Cancer*, 2001-2002
8. Editorial Board, *Clinical Cancer Research*, **2002-**
9. Editorial Board, *Current Cancer Therapy Reviews*, **2004-**

Journal Reviewer

Reviewed manuscripts for:

International Journal of Gynecologic Cancer (1993-present)
Cancer Immunology Immunotherapy (1994)
Cancer (1994)
Oncogene (1994)
Journal of Clinical Investigation (1995-present)
Gynecologic Oncology (1995-present)
Cancer Detection and Prevention (1995-present)
American Journal of Obstetrics and Gynecology (1996-present)
The Cancer Journal (1996-present)
International Journal of Radiation Oncology Biologyphysics (1998)
Cancer Research (1998-)
Clinical Cancer Research (1998-present)
Oncology (1998-present)
Journal of Immunotherapy (2000-present)
Experimental Cell Research (2001-present)

TEACHING

Within Current Institution
Formal Teaching

Courses Taught

Instructor, Immunology Program for Gyn/Onc Fellows/Residents (series of lectures), annually

Training Programs

Gynecologic Oncology Fellowing Training Program, annually

Other Educational Programs

N/A

Supervisory Teaching**Advisory Committees**

Member, Ph.D. Advisory Committee, G.S.B.S., (b) (6) 1994-1998
Chair, Ph.D. Advisory Committee, G.S.B.S., 1995-1999
Member, Ph.D. Advisory Committee, G.S.B.S., 2001
Member, M.D. Advisory Committee, G.S.B.S., 2002-2003
Chair, M.D./Ph.D., G.S.B.S., (b) (6) 2002-2005
Member, Ph.D. Advisory Committee, G.S.B.S., (b) (6) 2003

Supervisory Committees

Member, Ph.D., G.S.B.S., (b) (6) 1995-1999
Chair, Ph.D., G.S.B.S., 2000-2002
Chair, M.D./Ph.D., G.S.B.S., 2002-2005

Direct Supervision**Undergraduate and Allied Health Student**

(b) (6) Tutorial, Fall 1990
(b) (6) Tutorial Fall, 1994
(b) (6), Tutorial Spring 1995
(b) (6), Tutorial, Spring 1995

Medical Students

N/A

Graduate Students

(b) (6) Ph.D. G.S.B.S. 1994 - 1998
(b) (6), Ph.D., G.S.B.S. 1995 - 1999
(b) (6) Graduate Student G.S.B.S. Fall 1999
(b) (6), Graduate Student G.S.B.S. Fall 1999
(b) (6), Graduate Student G.S.B.S. Spring 2000
(b) (6), Graduate Medical Student G.S.B.S. Spring 2000
(b) (6) Graduate Student G.S.B.S. 2000-2002
(b) (6) Graduate Student G.S.B.S. Spring 2002
(b) (6) Graduate Student, G.S.B.S. Summer 2002
(b) (6) Graduate Medical Student G.S.B.S., 2002-2005
(b) (6), Graduate Student, G.S.B.S., Fall 2003

(b) (6) 2008-2010

Residents and Fellows

(b) (6), M.D. (Postdoctoral Fellow), U. T. M. D. Anderson, July 1992 – June 1993

(b) (6) M.D., Ph.D. (Postdoctoral Fellow), July 1992 – June 1993, Dutch Cancer Society, Utrecht, The Netherlands

(b) (6) M.D. (World Health Organization Fellow) June, 1996

(b) (6) M.D. (Postdoctoral Fellow) Asan Medical Center, Univ. of Ulsan, Seoul, Korea September 1997 – August, 1998

(b) (6) M.D., (Visiting physician/Observer) Bangkok Thailand 1998

(b) (6), M.D. (Postdoctoral Fellow), The Catholic University, Rome, Italy

(b) (6), M.D. (Postdoctoral Fellow) U. T. M.D. Anderson, July 1998 – June 1999

(b) (6), M.D., Ph.D. (Post Doctoral Fellow), April 1998 – March 2000, Prague, Czech Republic

(b) (6) M.D., Ph.D. (Postdoctoral Fellow), Charles University, Medical School, Hradec Kralove, Czech Republic 1995 – 1996, April 2001 – August 2001

(b) (6) M.D., Ph.D. (Visiting Assistant Professor), Nara Medical University, Nara, Japan, June 2003 –

Teaching Outside of Current Institution

CONFERENCES AND SYMPOSIA

Organization of National or International Conferences/Symposia (including chairing sessions)

Member, Organizing Committee; Co-Chair, Session V: Cancer Immunobiology, U.T. M.D. Anderson Cancer Center, “Cancer Immunity: Challenges for the Next Decade,” 56th Annual Symposium on Fundamental Cancer Research, Houston, Texas, October 14-17, 2003

Presentations at National or International Conferences

Invited

Invited speaker, “Development of a Cell Surface Reacting Monoclonal Antibody in Ovarian Cancer”, First International Conference on Human Antibodies & Hybridomas, Orlando, FL, April 17-20, 1990

Invited speaker, “Conventional Treatment Results in the Treatment of Epithelial Ovarian Cancer”, Sixth International Autologous Bone Marrow Transplantation Symposium, Sheraton Grand Hotel, Houston, TX, December 1-3, 1992

Invited speaker, Helene Harris Memorial Trust 8th International Biennial Forum on Ovarian Cancer, Houston, TX, March 2001

Invited speaker, Cancer Therapeutics Discovery Program – Winter Symposium – Vaccine Immunotherapy, Morning Session Co-Chairman, Crowne Plaza Hotel, Houston, TX January 12, 2002

Invited speaker, “Bioimmunotherapy Strategies for Ovarian Cancer, Cerus Corporation Science Retreat 2002, San Jose, CA, May 3-5, 2002

Invited speaker, “Non-cytotoxic (Bioimmunotherapeutic) Consolidation Approaches,” Second European Symposium on Ovarian Cancer, Polydome, Clermont-Ferrand, France, September 19-21, 2002

Invited speaker, “Intraperitoneal Delivery of Bioimmunotherapy Agents,” Helene Harris Memorial Trust 9th International Forum on Ovarian Cancer, Stratford-upon-Avon, England, March 24-28, 2003

Invited speaker, “The Cytokine/Chemokine Microenvironment of Ovarian Cancer,” Society for Gynecologic Investigation (SGI) Mini-Symposia on Immunobiology and Immunotherapy of Ovarian Cancer, The Westin Galleria, Houston, TX, March 26, 2004

Invited speaker, “IP Immunotherapy in Ovarian Cancer,” International Symposium on Peritoneal Therapy for Ovarian Cancer, University of Louisville, Louisville, KY, May 20-21, 2005

Invited speaker, “Peritoneal Immunotherapy,” Ovarian Cancer: Prevention and Detection of the Disease and its Recurrence, University of Pittsburgh, Pittsburgh, PA, October 24-25, 2005

Invited speaker, “Regional Biologic Therapy,” First International Symposium on Regional Cancer Therapies, David C. Koch Regional Perfusion Cancer Therapy Center, University of Pittsburgh School of Medicine, and UPMC Cancer Centers, Snowmass Village, CO, January 14-16, 2006

Other, Including Scientific Exhibitions

Seminar Invitations from Other Institutions

“Control of Chemotherapy Induced Nausea & Emesis”, University Hospital Zurich, Basel, Lausanne Switzerland Geneva, Utrecht Radboud Hospital, The Netherlands, December 2-5, 1986

"Gynecological Cancer", Texas Physicians Advisory Regional Mtg, Rio Grande, TX Aug 8, 1986

“General Overview of Gynecologic Cancer, Cervix and Endometrium”, Rio Grande Treatment Center; McAllen, TX Oct 15, 1986

“Ovarian Cancer”. Pasadena Bayshore Medical Center, Pasadena, TX”, Nov 6, 1986

“Update on Ovarian & Adenocarcinoma, Diagnosis and Treatment of Endometrial Carcinoma and Vulvar Carcinoma”, 55th Annual Post Graduate Convention The Alumni Association School of Medicine Loma Linda, CA, Mar 8-9, 1987

"Endometrial Cancer", Marshall Memorial Hosp, Marshall, TX, Nov 5, 1987

Round Table Discussion on Thiotepa ,Mt. Sinai Faculty NY, NY, June 29, 1988

“Monoclonal Antibodies”, Bionetics Research, Rockville, MD, Mar 2, 1989

“Antiemetic Roundtable”, Upjohn Company London, England, Moderator Round Table Discussion & Video Production, Sept 2-3, 1989

“Biologic Response Modifiers in Gynecologic Malignancies and Endometrial Cancer”, Southwestern Gynecologic Assembly Dallas, TX, Dec 5-7, 1991

"Novel Immunologic Strategies for the Treatment of Ovarian Carcinoma Based on Cell Surface Recognition", Texas A&M Univ Graduate Students & Faculty, College Station, TX, April 14, 1991

“IP Adoptive Immunotherapy with rIL-2 Expanded TIL Plus Low Dose rIL-2 in Patients with Advanced Ovarian Carcinoma”, Seventh Annual Conference on Clinical Immunology, Philadelphia, PA, Nov 13-15, 1992

“Update on Women’s Healthcare Issues”, Intracorp Rehabilitation Services, Endometrial Cancer Services (Upjohn), Irving, TX, Aug 21, 1993

Presented revised protocol to RAC and discussed TIL Trials, Recombinant DNA Advisory Committee NIH, Bethesda, MD, June 9, 1994

“New Biologic Therapy Approaches in Ovarian Cancer”, Grand Rounds Dept. of OB/GYN Faculty/Residents/Medical Students, UT Med Branch, Galveston, TX, March 29, 1995

“Dendritic Cells and Immune Responses in the Peritoneal Cavity,” RPR Gencell Santa Clara, CA, Dec 2, 1996

"Immunotherapy for Ovarian Cancer", Argonex Charlottesville, VA Sept 14, 1998

Lectureships and Visiting Professorships

Nurses Masters Degree Program UTMS, Houston, TX “Gynecologic Malignancies”, April 2, 1985

Grand Rounds UT MDACC, Houston, TX “Viral Oncolysates in Ovarian Cancer” June 14, 1985

Radiotherapy Planning Clinic UT MDACC, Houston, TX, “New Approaches in Ovarian Cancer”, June 27, 1985

Resident Lectures Parkway Hospital, Houston, TX, “Current Management of Endometrial Cancer”, July 12, 1985

Resident Lecture UT MDACC, Houston, TX, “Advanced Ovarian Cancer and Other Therapies, Aug 30, 1985

Parkway Hospital, Houston, TX “Current Management in Ovarian Cancer, Nov 22, 1985

Prevention Symposium UT MDACC, Houston, TX, “Viral Augmentation Immunotherapy in Ovarian Cancer”, Dec 2, 1985

Second Hybridoma Symposium UT MDACC, Houston, TX "Possibilities of Human Monoclonal Antibody Production Using PBL from Actively Immunized Ovarian Cancer Patients" Jan 23, 1986

Nurses Masters Degree Program, UTMS, Houston, TX “Cancer of the Female Genital Organs", Feb 19, 1986

Videotaping, produced by Upjohn International, Filmed by UT MDACC, Dept. of Med Comm. Houston, TX, “Control of Chemotherapy Producing Nausea & Emesis”, April 8, 1986

Texas Advisory Comm. UT MDACC, Houston, TX, “Immunotherapy in Gynecologic Cancer", April 18, 1986

Outside Review for Department of GYN, UT MDACC, Houston, TX “Overview of Research in Gynecology”, Aug 4, 1986

Tumor Board Meeting, Memorial City Hosp, Houston, TX, “Gynecologic Cancer” Sept 4, 1986

Morning Rounds, Fellows & Residents, UT MDACC, Houston, TX “Endometrial Cancer”, Sept 9, 1986

Stem Cell Assay Study Group, UT MDACC, Houston, TX, “Stem Cell Assay to Monitor Biologic Therapy”, Sept 9, 1986

UT Medical School OB/GYN Department, Houston, TX, “Cervical Cancer & Endometrial Cancer”, Oct 27, 1986

Morning Rounds Fellows & Residents UT MDACC, Houston, TX, “Antiemetic Therapy”, Dec 10, 1986

Division of Surgery Research Seminars, UT MDACC, Houston, TX, “Active Immunization in Gynecologic Cancers” April 13, 1987

Department of Cancer Prevention and Control Seminar, HMB, Houston, TX, “Viral Oncolysates and Gynecologic Cancers”, May 1, 1987

Third Annual Texas Medical Center Hybridoma Mtg, UT MDACC, Houston, TX, “Glycolipid Markers in Epithelial Ovarian Cancer”, May 29, 1987

Division of Surgery Research Seminars, UT MDACC, Houston, TX, “Viral Oncolysates in Gynecologic Cancer”, June 5, 1987

Department of Cancer Prevention & Control UT MDACC, Houston, TX, “Human Tumor Reactive MoAbs Directed Against Ovarian & Uterine Carcinomas”, Sept 14, 1990

Visiting Primary Care Physicians-Abilene, TX, MDACC, Houston, TX, “New Directions in the Treatment of Ovarian Cancer”, Oct 25, 1990

School of Public Health Houston, TX, “Role of Surveillance Committee in Clinical Research”, Nov 12, 1990

Houston Oncology, Research Group MDACC, Houston, TX, “New Trials in Ovarian Cancer”, Jan 24, 1991

Biotechnology Drug Delivery Workshop, St. Lukes Episcopal Hosp., Houston, TX, “Biotherapy in Cancer”, Feb 15, 1991

The Wilkerson Group, New York, NY Teleconference, “Current Treatment Patterns for Cervical Cancer” April 8, 1991

Jr. League of Houston, TX, "Ovarian Cancer", May 8, 1991

Division of Laboratory Medicine, MDACC, Houston, TX, “Therapeutic Strategies for Ovarian Cancer Involving Specific Cell Surface Recognition”, June 14, 1991

Dept. of Gen. Surg. Employees’ Program, Houston, TX, “Current Treatments in Ovarian Cancer”, Aug 14, 1991

Dept. of OB/GYN UT Health Science Center, Houston, TX, “Novel Immunologic Strategies for the Treatment of Ovarian Carcinoma Based on Cell Surface Recognition” Sept 24, 1991

Hoffman-LaRoche Preceptorship for Physicians from Europe held at MDACC, Houston, TX, “Treatment of Ovarian Carcinoma with rIL-2 Expanded TILs + rIL-2”, July 6, 1992

Lecture series to Fellows & Residents, UT MDACC Immunology Program, Aug. 1992
Immunobiology of Cancer "Applications of Immunology in Cancer Control"
Houston, TX, Cellular & Molecular Mech in Cancer Control" October 20-23, 1992

Weekly Lecture Series, "Adoptive Immunotherapy in Ovarian Cancer, Houston, TX,
(Biological Response Modifiers) (Drs. (b) (6)) MDACC, Mar 29, 1993

French Cancer Centers Directors' Visit to MDACC, Open Discussion on Standard
Practice Guidelines, July 19, 1993

Cancer Fighters of Houston, Inc., (MDACC) "Human Tumor Cell Surface Reactive
MoAbs in Ovarian Cancer", Sept 9, 1993

Schering Preceptorship, MDACC, "Alternative Uses of Cytokines Including IP
Administration", Sept 15, 1993

Cetus Preceptorship MDACC, Houston, TX, "Alternative Uses of Cytokines Including
IP Administration", Sept 22, 1993

Schering Domestic Preceptorship, MDACC, "Alternative Uses of Cytokines Including IP
Administration", Sept 14, 1993

Faculty Seminary Series, (Dept of Immunol) MDACC, "IP Adoptive Immunotherapy
with TIL", Dec 15, 1993

Lecture series to Gyn/Onc Fellows and Residents, MDACC, Immunology Program, Feb
and Mar 1994

Schering Preceptorship (Schering Plough) MDACC, "Investigational Compounds and
Biological Therapy in Ovarian Carcinoma: Mar 18, 1994

Schering Preceptorship (Schering Plough) MDACC, "Investigational Compounds and
Biological Therapy in Ovarian Carcinoma", June 17, 1994

Hoffman-LaRoche M.D.'s Clinical Exchange Program MDACC, "Investigational
Compounds for Ovarian Cancer", Sept 13, 1994

Hoffman-LaRoche M.D.'s Clinical Exchange Program MDACC, "Investigational and
Biological Compounds for Ovarian Cancer", Sept 27, 1994

Schering Domestic Reps, MDACC, "Alternative uses of Cytokines Including IP
Administration", Oct 5, 1994

Hoffman LaRoche MD's Clinical Exchange Program MDACC, "Investigational
Compounds & Biological Therapy in Ovarian Cancer", Nov 8, 1994

Hoffman LaRoche MD's Clinical Exchange Program MDACC, "Development of IP
Adoptive Immunotherapy Strategies for Ovarian Cancer", Dec 19, 1994

Hoffman LaRoche MD's Clinical Exchange Program MDACC, "Investigational Compounds & Biological Therapy in Ovarian Carcinoma", Feb 9, 1995

Hoffman LaRoche Clinical Exchange Program, (Belgian Hematologists), MDACC, "Alternative uses of IL-2 Including IP Administration", Feb 14, 1995

Schering Int Clinical Exchange Program, MDACC, "Investigational Compounds & Biological Therapy in Ovarian Cancer", Mar 14, 1995

Schering Domestic Preceptorship Program, MDACC, "Alternative uses of Cytokines, Including IP Administration", April 12, 1995

Hoffman LaRoche Clinical Exchange Program, MDACC, "Investigational Compounds & Biological Therapy in Ovarian Cancer", April 25, 1995

Hillcrest Fentress Cancer Center, Waco, TX "Current Directions in Treatment of Ovarian Cancer", April 26, 1995

The Univ. of Texas Dept. of Internal Medicine, Clinical Research Center (Mentor Program) "*Ex vivo* expanded Tumor Infiltrating Lymphocytes as Immunotherapy for Epithelial Ovarian Cancer", May 8, 1995

The Univ. of Texas Advisory Group Committee, "Policies & Procedures for Clin. Research Committee Protocols", May 11, 1995

Schering International Preceptorship Program, MDACC, "Alternative Uses of Cytokines, including IP Administration", June 7, 1995

Chiron Cetus Clinical Exchange Program, MDACC, "IP Administration of IL-2 in Ovarian Carcinoma", June 17, 1995

Hoffman LaRoche Clinical Exchange Program, MDACC, "Investigational Compounds & Biological Therapy in Ovarian Cancer", June 20, 1995

Schering Domestic Preceptorship Program MDACC "Alternative Uses of Cytokines Including IP Administration", Aug 8, 1995

Hoffman LaRoche Clinical Exchange Program MDACC, "Investigational Compounds & Biological Therapy in Ovarian Cancer", Sept 12, 1995

Schering Clinical Exchange Program, MDACC, "Investigational Compounds & Biological Therapy in Ovarian Cancer", Sept 19, 1995

Chiron Clinical Exchange Program, MDACC, "Intraperitoneal Administration of IL-2 in Ovarian Carcinoma", Sept 30, 1995

Hoffman LaRoche Clinical Exchange Program, MDACC, “Alternate Uses of IL-2 Including IP Administration”, April 30, 1996

Lecture series to Gyn/Onc Fellows and Residents, Immunology Program, May and June, 1996

Hoffman LaRoche Clinical Exchange Program, MDACC, “Investigational Compounds & Biological Therapy in Ovarian Cancer”, June 18, 1996

Schering Clinical Exchange Program, MDACC, “Alternate Uses of Cytokines Including IP Administration”, June 26, 1996

Hoffman LaRoche Clinical Exchange Program, MDACC, “Investigational Compounds & Biological Therapy in Ovarian Cancer”, July 16, 1996

Schering Plough Domestic Preceptorship, MDACC, “Alternate Uses of Cytokines Including IP Administration” August 13, 1996

Hoffman LaRoche Clinical Exchange Program, MDACC, “Investigational Compounds and Biological Therapy in Ovarian Cancer”, September 10, 1996

Human Protection Workshop, MDACC, “Critical Issues in Human Research, Academic Creativity, Minority Participation, and Patient Protection”, Nov 1 –2, 1996

Nuclear Medicine, MDACC, “Progress Towards Activation of Immunity *In Vivo* in Ovarian Cancer”, January 7, 1997

Schering Domestic Clinical Exchange Program, MDACC, “Alternative Uses of Cytokines, Including IP Administration”, January 23, 1997

Hoffman LaRoche Clinical Exchange Program, MDACC, “Alternative Uses of Cytokines, Including IP Administration”, February 11, 1997

Schering Domestic Clinical Exchange Program, MDACC, “Alternative Uses of Cytokines, Including IP Administration”, April 4, 1997

Biotechnology Conference, Houston, TX “Monoclonal Antibodies Reactive with Cell Surface of Human Ovarian Cancer”, June 9, 1997

Hoffman LaRoche Clinical Exchange Program, MDACC, “Alternative Uses of Cytokines, Including IP Administration”, June 17, 1997

Tumor Immunobiology Conference (GSBS), Houston, TX, “Cellular Immunotherapy”, October 20, 1997

Hoffman LaRoche Clinical Exchange Program, MDACC, “Investigational Compounds and Biological Therapy in Ovarian Cancer”, October 28, 1997

Hoffman LaRoche Clinical Exchange Program, MDACC, “Investigational Compounds and Biological Therapy in Ovarian Cancer”, November 18, 1997

Grand Rounds, UT Medical School, Department of Pathology & Lab Medicine, Houston, TX, “Biologic Therapy of Cancer/Immunotherapy”, January 7, 1998

Human Cancer Immunotherapy Program, Houston, TX, “Vaccines in Ovarian Cancer”, May 23, 1998

Rhone-Poulenc Rorer, MDACC, “Investigational Compounds & Biologic Therapy in Ovarian Cancer”, June 4, 1998

Schering Domestic Repts, MDACC, “Alternative Uses of Cytokines, Including IP Administration, June 12, 1998

Grand Rounds, MDACC, “Intraperitoneal Based Immunotherapy for Malignancies of the Peritoneal Cavity”, October 9, 1998

Hoffman LaRoche Preceptorship, MDACC, “Investigational Compounds & Biologic Therapy in Ovarian Cancer”, November 17, 1998

Immunotherapy Program, UT Medical School, “IL-12 Cytokine Therapy”, November 21, 1998

Immunology Program for GYN/ONC Fellows, “Antigens, Antibodies and Complement”, June 14, 1999

Immunology Program for GYN/ONC Fellows, “Cytokines and Chemokines”, Tissues and Cells of the Immune System, including Immediate and Delayed Hypersensitivity Reactions”, June 22, 1999

Immunology Program for GYN/ONC Fellows, “Immunotherapy Modalities, Cytokine Therapy Applications, Including New Agents, mAbs, Production and Application in Diagnosis and Therapy”, June 28, 1999

Clinical Research Curriculum MDACC, “Research Design, Observational Studies”, September 22, 1999

Tumor Immunobiology (GSBS), “Principles of Cellular Immunotherapy”, October 7, 1999

Advanced Reproductive Biology Course (Dr. (b) (6)) MDACC, “Malignancies of the Female Reproductive Tract”, October 21, 1999

Vaccine Working Group of the Human Cancer Immunotherapy Program (Dr. (b) (6)), “Immunotherapy with MVA-HPV-IL-2 in Cervix Cancer”, January 13, 2000

Immunology Program for GYN/ONC Fellows, "Vaccines for cervical cancer", March 8, 2000

Research Nurse Orientation Program, MDACC, ""Protection of Human Subjects from the Risks of Clinical Research", June 22, 2000

Research Nurse Orientation Program, MDACC, ""Protection of Human Subjects from the Risks of Clinical Research", October 12, 2000

Immunology Program for GYN/ONC Fellows, "Cytokines/Vaccine Protocols/Antigens, Antibodies and Complement, Tissues & Cells of Immune System " January, 2001

Research Nurse Orientation Program, MDACC, "Protection of Human Subjects from the Risks of Clinical Research" January 8, 2001

Tumor Immunobiology Course, MDACC (GSBS), "Principles of Cellular Immunotherapy", September 27, 2001

CanCare, Cancer Support Network, "Ask the Doctor" Panel Discussion – Education Event, Houston, TX, November 11, 2001

InterMune, Oncology Meeting, "Advancements in ovarian cancer management: cytokines and other novel agents in development", Dallas, TX, November 13, 2001

Cancer Therapeutics Discovery Program, "Vaccine Immunotherapy", Winter Symposium, Crowne Plaza, Houston, TX Co-Chairman Morning Session, January 12, 2002

Immunology Program for GYN/ONC Fellows, MDACC, "Tumor Immunobiology in Gynecologic Cancer," December 13, 2002

CCOP Annual Investigators Meeting, "Bioimmunotherapy of Ovarian Cancer," Westin Galleria, Houston, TX, March 1, 2003

Helene Harris Memorial Trust 9th Biennial International Forum on Ovarian Cancer, "Intraperitoneal Delivery of Biologic Agents," Stratford-upon-Avon, March 25-27, 2003

Journal Club for GYN/ONC Fellows, MDACC, March 5, 2004

Visiting Professorships:

University of Madrid, Madrid, Spain, "Hormone Therapy in Ovarian Cancer", May, 1985

Armand Hammer Symposium Salk Institute, San Diego, California, "Biological Therapy", Sept 1985

Cetus Corporation Seminar, San Francisco, California, "Immunotherapy of Ovarian Cancer", Dec 1985

14th Int'l Cancer Congress, Budapest, Hungary, "Methylprednisolone as an Antiemetic," Aug 1986

Rio Grande Center Treatment Center, McAllen, TX, "General Overview of Gynecological Cancer; Cervix and Endometrium", Oct 1986

Upjohn, Switzerland and Holland, "Chemotherapy Induced Nausea & Vomiting", Dec 1986

55th Annual Postgraduate Convention, The Alumni Association School of Medicine, Loma Linda, CA, "Update on Ovarian Adenocarcinoma", Mar 1987

Marshall Memorial Hospital, Marshall, TX, "Endometrial Cancer", Nov 1987

Mt. Sinai Faculty New York, NY, "Round Table Discussion on Thiotepe", June 1988

Guest Professor, Grand Rounds, Wayne State University, Detroit, Michigan, "BRM's as they apply to Gynecologic Malignancies & an Overview on Endometrial Cancer", Nov 1988

Guest Professor, University of Witwatersrand, Johannesburg, S. Africa, "GYN/ONC Clinic with Students & Residents", "BRM Lecture", July 1989

Moderator CINE (Upjohn Company), Round Table Discussion on "Anti-emetic Therapy", London, England, Sept 1989

Guest Professor, John Peter Smith Hospital, Ft. Worth, TX, "New Therapeutic Approaches for GYN Cancers in 1990's", Feb 1990

Visiting Professor, Primary Care Physicians, Abilene, TX, "New Directions in the Treatment of Ov Ca", Oct 1990

Biotechnology Drug Delivery Workshop, St. Lukes Episcopal Hospital, Houston, TX "Biotherapy in Cancer", Feb 1991

Visiting Professor, Spohn Hospital Tumor Conference, Corpus Christi, TX "Current Concepts in Immunology", Oct. 1991

Visiting Professor, Southwestern Gynecologic Assembly, Dallas, TX, "Biologic Response Modifiers in Gyn Malignancies & Endometrial Cancer", December 1991

Texas A & M University, Bryan College Station, TX, Graduate Students & Faculty "Novel Immunologic Strategies for the Treatment of Ovarian Carcinoma Based on Cell Surface Recognition", April 1992

Intracorp Rehabilitation Services (Upjohn), Irving, Texas, “Update on Women’s Healthcare Issues”, (Endometrial Cancer), Aug 1993

2nd European Congress in Gynecological Endoscopy & New Surgical Techniques, Heidelberg, Germany, “Regional Clinical Responses Following IP Injection of Allogeneic VO in Patients with EOC”. Co-Chaired Session with Drs. V. Schirrmacher and G. Bastert, “New Trends in Chemotherapy and Immune Therapy”, Oct 1993

Visiting Professor, Department OB/GYN, UT Med Branch, Galveston, TX, “New Biologic Therapy Approaches in Ov Ca”, Mar 1995

Guest Professor, Hillcrest Fentress Cancer Center, Waco, TX, “Current directions in Treatment of Ov Ca”, April 1995

Guest Professor, Arlington Cancer Center, Arlington, TX, “Bioimmunotherapy of Peritoneal Carcinomatosis-New Directions”, Feb 1997

1) Samsung Medical Center Seoul, Korea Guest Professor, “Current Research Issues in Gynecologic Cancers”; 2) Asan Medical Center, Seoul, Korea Guest Professor, “Human Monoclonal Antibodies in Gynecologic Cancers”; 3) Seoul National University Hospital, Seoul, Korea, Guest Professor, “Current Therapeutic Modalities in Ovarian Cancer”, Sept 1997

Grand Rounds The University of Texas Guest Professor, Department of Pathology and Laboratory Medicine, "Biologic Therapy of Cancer/Immunotherapy", Jan 1998

Visiting Professor, Catholic University, Rome, Italy, Department of Obstetrics/Gynecology, "Role of Cytokines in Normal & Neoplastic Ovary Biologic and Clinical Aspects", Oct 1998

Guest Professor, Grand Rounds - UT MDACC, "Approaches to Optimizing Intraperitoneal Active Immunity", Oct 1998

Genetics Institute, Cambridge, MA, Invited to present clinical and immunologic results of IL-12 trial, June 1999

Grand Rounds, Baylor College of Medicine, Department of Obstetrics and Gynecology, “Regional Biologic Therapy-New Projects,” January 25, 2006

Other Presentations (state, local) Conferences

N/A

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

Fellow, Royal College of Obstetricians and Gynecologists, London England, 1984-present

Member, Harris County Medical Society, 1978-present

Member, Texas Medical Association, 1978-present
Member, Tissue Culture Association, 1978-present
Member, American Medical Association, 1978-present
Member, Houston Gynecological Obstetrical Society, 1979-present
Member, American Radium Society, 1979-present
Fellow, American College of Obstetricians & Gynecologists, 1980-2008
Life Member, American College of Obstetricians & Gynecologists, 2009-present
Member, Houston Surgical Society, 1982-present
Member, Society of Surgical Oncology, Inc., 1983-present
Member, The Felix Rutledge Society, 1983-present
Member, American Association for Cancer Research, 1983-2008
Member Emeritus, American Association for Cancer Research, 2008-present
Member, American Association for Advancement of Science, 1984-present
Fellow, American College of Surgeons, 1984-present
Member, American Society of Clinical Oncology, 1985-present
Member, American College of Surgeons, South Texas Chapter, 1986-present
Member, New York Academy of Science, 1986
Membership Council, Houston Surgical Society, 1987-1990
Member, International Gynecologic Cancer Society, 1991-present
Elected Member, The American Association of Immunologists, 1994-present